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RÉSUMÉ 
Rôle de NLRX1 dans l'absorption et la libération de glutamate par les astrocytes 
Par 
Shaimaa Mahmoud 
Programme d'immunologie 
Mémoire présenté à la Faculté de médecine et des sciences de la santé en vue de l’obtention du 
diplôme de maitre ès sciences (M.Sc.) en immunologie, Faculté de médecine et des sciences de 
la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
Le glutamate est le principal neurotransmetteur excitateur du système nerveux central (SNC). 
Lorsque le glutamate est libéré dans la fente synaptique par les neurones présynaptiques, seulement 
20% du glutamate libéré est absorbé par les neurones postsynaptiques. Le glutamate restant dans 
l'espace extracellulaire doit être collecté puisqu’il peut être toxique pour les neurones. Une 
exposition excessive ou prolongée des neurones au glutamate induit une hyperstimulation des 
récepteurs du glutamate, conduisant éventuellement à la mort neuronale dans le cadre d'un 
processus appelé « excitotoxicité du glutamate ». 
Les astrocytes sont les cellules qui absorbent la majorité du glutamate extracellulaire grâce à 
leur expression de transporteurs d’acides aminés excitateurs 1 et 2 (EAAT1 et EAAT2). Les 
astrocytes absorbent le glutamate contre le gradient de concentration, ce qui demande un taux élevé 
d’ATP intracellulaires. Un haut taux de stress oxydatifs inhibe l’absorption du glutamate.  
Les astrocytes libèrent également des traces de glutamate, par exocytose médiée par le Ca2+, 
dans l'espace extracellulaire, ce qui permet de synchroniser les neurones adjacents. Toute anomalie 
astrocytaires entraîne une absorption réduite ou une libération excessive de glutamate prédisposant 
à une excitotoxicité du glutamate. Ces anomalies sont présentes dans plusieurs troubles du SNC.  
NLRX1 est un capteur immunitaire inné de la famille des récepteurs de type NOD. Il s'agit 
d'une molécule anti-inflammatoire qui inhibe les voies de signalisation telles que NF-κB et RIG-
1-MAVS. NLRX1 est aussi considéré un facteur de survie puisqu’il inhibe la mort neuronale. 
Contrairement aux autres NLRs, NLRX1 est localisé dans les mitochondries. NLRX1 augmente 
la fission mitochondriale et la production d'ATP et il inhibe le stress oxydatif. 
Par conséquent, nous avons émis l’hypothèse qu’en renforçant les fonctions mitochondriales 
dans les astrocytes, NLRX1 améliore l’absorption du glutamate et inhibe la libération de glutamate 
par les astrocytes. Pour répondre à notre hypothèse, nous avons étudié le rôle de NLRX1 dans la 
capture et la libération du glutamate par des cultures d'astrocytes primaires de souris WT et Nlrx1-
/- et les mécanismes par lesquels NLRX1 atténue ses effets. Nos résultats ont révélé que NLRX1 
potentialise la capture de glutamate astrocytaire en augmentant la production d’ATP 
mitochondriale et en prévenant le stress oxydatif, qui à leur tour maintiennent les fonctions saines 
de EAAT1 et EAAT2 dans les astrocytes. NLRX1 supprime également la libération de glutamate 
astrocytaire en réprimant la libération de Ca2+ du réticulum endoplasmique (ER), ce qui supprime 
l'exocytose du glutamate médiée par le Ca2+. Ensemble, nos données suggèrent que NLRX1 est un 
régulateur potentiel de l'homéostasie du glutamate dans le SNC. 
 
Mots-clés: NLRX1, absorption de glutamate, libération de glutamate, astrocytes, excitotoxicité. 
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SUMMARY 
Role of NLRX1 in glutamate uptake and release by astrocytes 
By 
Shaimaa Mahmoud 
Immunology Program 
Thesis presented to Faculty of Medicine and Health Sciences for the obtention of a Master’s 
degree (M.Sc.) in Immunology, Faculty of medicine and health sciences, Université de 
Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS). When 
glutamate is released from the presynaptic neurons to the synaptic cleft, only 20% of the released 
glutamate is taken up by the postsynaptic neurons to transmit the excitatory signals. The remaining 
glutamate (80% or more) must be collected from the extracellular space as it is potentially toxic to 
neurons. Excessive or prolonged exposure of neurons to glutamate induces hyperstimulation of the 
glutamate receptors in neurons that eventually leads to neuronal death in a process known as 
“glutamate excitotoxicity”. 
The process of glutamate uptake from the extracellular space is achieved mainly by astrocytes, 
which are the most numerous cell type in the CNS. Astrocytes express excitatory amino acid 
transporters 1 and 2 (EAAT1 and EAAT2) which are responsible for glutamate uptake. To uptake 
glutamate against its concentration gradient, EAAT1 and EAAT2 consume a high level of 
intracellular ATP. By contrast, oxidative stress inhibits their function of glutamate uptake. 
In addition to glutamate uptake, recent studies demonstrate that astrocytes release traces of 
glutamate to the extracellular space, which helps synchronize and reinforce the firing of the 
adjacent neurons. Astrocytes release glutamate mainly by Ca2+-mediated exocytosis. Any defect 
in astrocytic functions that results in reduced glutamate uptake and/or excess glutamate release 
predisposes to glutamate excitotoxicity, as occurs in many CNS disorders. 
NLRX1 is an innate immune sensor from the non-inflammasome NOD-like receptors’ family. 
It is known as an anti-inflammatory molecule that inhibits NF-κB and RIG-1-MAVS signaling 
pathways. NLRX1 also acts as a survival factor that inhibits neuronal death. Unlike other NLRs, 
NLRX1 is localized to the mitochondria and was shown to enhance mitochondrial fission and ATP 
production while it inhibits oxidative stress. 
Therefore, we hypothesized that by enhancing mitochondrial functions in astrocytes, NLRX1 
enhances glutamate uptake and inhibits glutamate release by astrocytes. To address our hypothesis, 
we investigated the role of NLRX1 in glutamate uptake and release by primary astrocyte cultures 
from WT and NLRX1-/- mice and the mechanisms by which NLRX1 mediates its effects. Our 
results revealed that NLRX1 potentiates astrocytic glutamate uptake by enhancing mitochondrial 
ATP production and preventing oxidative stress, which in turn maintain healthy functions of 
EAAT1 and EAAT2 in astrocytes. NLRX1 also suppresses astrocytic glutamate release by 
repressing Ca2+ release from the endoplasmic reticulum (ER), which in turn suppresses Ca2+-
mediated glutamate exocytosis. Taken together, our data suggest that NLRX1 is a potential 
regulator of glutamate homeostasis in the CNS. 
Keywords: NLRX1, glutamate uptake, glutamate release, astrocytes, excitotoxicity. 
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1. INTRODUCTION 
1.1.  The Central Nervous System and its cellular components 
The central nervous system (CNS) consists of the brain and the spinal cord. It is the fascinating 
system in our body that controls all our voluntary and involuntary movements, sensations and 
higher cognitive functions such as the memory, emotions, thinking, learning…. etc. It also controls 
our internal body functions including, but not restricted to the heart rate, respiration, and digestion. 
In order to perform its highly integrated functions, the CNS contains two major types of cells: 
neurons and glial cells, which include astrocytes, oligodendrocytes, and microglia. 
1.1.1. Neurons and neurotransmitters 
Neurons are the main functional unit in the CNS. They are responsible for the transmission of 
signals from the body to the CNS and vice versa. The structure of neurons is divided into three 
main parts, which are: the cell body, the dendrites, and the axon (Figure 1). The neuronal cell 
body is the central part of the neuron that contains the nucleus and all the organelles necessary for 
the proper neuronal function (Jacobson and Marcus 2008). Many projections arise from the cell 
body, that are called the dendrites. They are responsible for the transmission of signals from the 
presynaptic to the postsynaptic neurons at the regions of the synapses (Vanderah, Gould, and 
Preceded by (work): Nolte n.d.). The longest projection from the cell body is called the axon, that 
ends with the nerve terminal. The axon is covered by the myelin sheath, which is a lipid bilayer 
that helps to strengthen and speed up the signal transmission along the axon, through what is called 
the salutatory conduction (Jacobson and Marcus 2008). The fast propagating signals travel along 
the axons in the form of electrical impulses known as the “action potential”, while the transmission 
from one neuron to the next occurs in a chemical form, through molecules known as 
“neurotransmitters” (Jacobson and Marcus 2008). 
1.1.1.1. Functions of neurotransmitters 
According to their functions, neurotransmitters could be excitatory, inhibitory or modulatory 
(Deutch 2013): 
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• Excitatory: These transmitters are likely to induce depolarization in the postsynaptic neuron 
and generate an action potential. Glutamate is the major excitatory neurotransmitter in the 
CNS. Epinephrine and norepinephrine are also common excitatory neurotransmitters. 
• Inhibitory: Transmitters that are more likely to induce hyperpolarization in the postsynaptic 
neuron and inhibit the generation of the action potential. The most common inhibitory 
neurotransmitter in the brain is ɣ-aminobutyric acid (GABA), while glycine is the most 
common one in the spinal cord. 
• Modulatory: These transmitters can modulate the action of other neurotransmitters. They 
diffuse to affect a larger number of neurons than the excitatory or the inhibitory 
neurotransmitters; however, they conduct a slower effect. 
1.1.1.2. Types of neurotransmitters 
According to the structure of neurotransmitters (Deutch 2013), they are classified into: 
• Amino acids, such as: 
Glutamate: The predominant excitatory neurotransmitter in the CNS that plays a role in 
cognitive functions such as memory and learning. 
GABA: Inhibitory neurotransmitter that is involved in vision, motor control, and the regulation 
of anxiety. 
• Acetylcholine: plays a role in both the central and the peripheral nervous systems. In the CNS, 
it is involved in cognitive functions such as memory and learning. 
• Monoamines: examples are: 
Epinephrine and norepinephrine: play a role in the alertness in cases of dangers or stress. 
Serotonin: participates in the regulation of the mood, sleep, anxiety, sexuality, and appetite. 
Dopamine: plays a major role in the coordination of body movements. 
• Peptides: include oxytocin, which plays a role in social recognition, bonding, and sexual 
reproduction, and endorphins, that inhibit pain signals and stimulate the feeling of euphoria. 
• Purines: such as adenosine and adenosine triphosphate (ATP). 
• Gas transmitters: involving nitric oxide and carbon monoxide. 
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Figure 1: Structure of neurons and synapses. Representative scheme of a typical neuron 
containing the cell body (soma) with the dendrites and the axon covered by myelin and ends with 
the axon terminal. The detailed structure of the synapse is presented on the left side of the figure. 
It shows the presynaptic and the postsynaptic neurons, with space in between known as the 
synaptic cleft where the neurotransmitter is released. (Untitled image licensed by Khan Academy 
under CC-BY-NC-SA and is available for free at www.khanacademy.org). 
1.1.2. Oligodendrocytes 
They represent a type of glial cells in the CNS. The main function of oligodendrocytes is to 
form the myelin sheath around the axons (Jacobson and Marcus 2008). Myelin is a lipid layer that 
is formed by a sheet of the oligodendrocyte’s plasma membrane, and a single oligodendrocyte can 
form myelin sheaths for several axons. Myelin sheath has a protective role for the axon against 
degeneration (Fitzner et al. 2006). It also wraps the axon in a non-continuous manner, leaving bare 
areas of the axon known as the “nodes of Ranvier”. As the action potential is traveling along the 
axon, the electrical impulses jump across the nodes of Ranvier, which helps to accelerate and 
reinforce the signal transmission (Byrne and Roberts 2009). In addition to myelin formation, 
oligodendrocytes release several neurotrophic factors such as glial-derived neurotrophic factor 
(GDNF), brain-derived neurotrophic factor (BDNF), and insulin-like growth factor-1 (IGF-1) 
(Bradl and Lassmann 2010). 
Nodes of Ranvier 
Oligodendrocytes 
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1.1.3. Microglia 
They are the professional innate immune cells in the CNS. Microglia represent the tissue-
resident macrophages, and they express the specific macrophage markers such as CD11b, CD14, 
CSF1R, CD80/86, and MHC-II (Graeber and Streit 2010; Kettenmann et al. 2011; Saijo and Glass 
2011). They represent 10 to 15% of the total glial cells in the CNS (Nayak, Roth, and McGavern 
2014) and they are found in the brain, spinal cord, retina and optic nerve (Goldmann and Prinz 
2013). Unlike other glial cells, they possess a characteristic morphology. In the resting state, they 
are highly ramified cells which allow them to scan the environment of the CNS for the presence 
of pathogens or damaged tissue, with the alternative extension and retraction of their ramifications. 
When microglia become activated, they retract their ramifications and acquire a rounded or 
ameboid shape (Nayak et al. 2014). Microglia play a role in neurogenesis, neuroprotection, and 
synapse formation, in addition to their innate immune functions (Shastri, Bonifati, and Kishore 
2013). Like macrophages, microglia function as phagocytic cells and antigen-presenting cells on 
MHC-II (Nayak et al. 2014; Shastri et al. 2013). In case of CNS pathology, microglia are 
classically activated to the inflammatory M1 phenotype, which release various pro-inflammatory 
molecules such as IL-1β, TNF-α, IL-6, CCL5, ROS, NO, iNOS, that skew the adaptive immune 
response towards the inflammatory phenotypes. By contrast, if microglia are alternatively 
activated to M2 subtype, they release regulatory cytokines such as IL-10 and TGF-β that inhibit 
inflammation and promote tissue repair (Goldmann and Prinz 2013; Kettenmann et al. 2011). 
1.1.4. Astrocytes 
They are the most plentiful cell type in the CNS, as their number exceeds the number of 
neurons by more than 5-folds (Liu et al. 2018). Astrocytes are star-shaped cells that connect to 
each other by gap junctions. They also form extensive connections with the blood vessels and 
neurons; therefore, they coat the CNS in a continuous and non-overlapping mechanism (Sofroniew 
and Vinters 2010). 
According to their morphology, astrocytes are classified into two main types, protoplasmic 
and fibrous astrocytes (Figure 2). Protoplasmic astrocytes are found in the gray matter, and they 
were shown to envelop synapses. They exhibit a characteristic morphology with numerous short 
fine branches. Fibrous astrocytes are present in the white matter, and they are characterized by 
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their long fiber-like processes, by which they connect to the nodes of Ranvier (Sofroniew and 
Vinters 2010). 
Astrocytes perform several vital functions in the CNS that maintain the homeostasis and 
ensure proper neuronal functions. During ontogeny, astrocytes play an essential role in the 
development of both white and gray matters. They form molecular boundaries and release several 
mediators such as “thrombospondin”, that guide the formation and growth of axons and synapses 
(Christopherson et al. 2005; Powell and Geller 1999). Through their connections to the blood 
vessels, astrocytes control the amount of blood flow to neurons, by releasing molecular mediators 
such as prostaglandin E (PGE), nitric oxide (NO) and arachidonic acid (AA), that modulate the 
diameter of the blood vessel according to the neuronal activity (Gordon, Mulligan, and MacVicar 
2007). Astrocytes also uptake glucose from the blood, convert it to lactate and provide it to neurons 
as a source of energy (Suh et al. 2007). Additionally, they store glycogen, and by glycogenolysis, 
they maintain the energy support to the neurons in case of hypoglycemia or increased neuronal 
activity (Pellerin et al. 2007). Moreover, Astrocytes’ end-feet support the blood-brain-barrier 
(BBB) and maintain its integrity (Abbott, Rönnbäck, and Hansson 2006). The BBB is a diffusion 
barrier that protects the CNS from the blood-born infections and harmful substances. It is formed 
by the cerebral capillary endothelial cells, capillary basement membrane, perivascular pericytes, 
and astrocytes’ end-feet (Ballabh, Braun, and Nedergaard 2004). Through astrocytes’ ion channels 
(such as Ca2+ and K+), aquaporin-4 water channel, and Na+/H+ exchanger, astrocytes maintain the 
ionic and fluid balance and regulate the pH in the CNS, respectively (Obara, Szeliga, and Albrecht 
2008; Simard and Nedergaard 2004). They also play a very important role in the homeostasis of 
neurotransmitters. Astrocytes uptake the excess synaptically-released neurotransmitters such as 
glutamate, GABA, and glycine from the extracellular space, metabolize them using specific 
enzymes expressed by astrocytes and release their metabolites back to the extracellular space, 
where they are taken up by neurons to resynthesize active neurotransmitters (Mahmoud et al. 2019; 
Sofroniew and Vinters 2010). In addition to the uptake of neurotransmitters, astrocytes release 
traces of transmitters, known as “Gliotransmitters” such as glutamate, GABA, D-serine and ATP 
to the adjacent neurons, which help to synchronize and strengthen their firing (Hamilton and 
Attwell 2010; Mahmoud et al. 2019). Moreover, astrocytes release many growth factors and 
neuroactive steroids such as estradiol and progesterone to maintain normal synaptic functions 
(Barres 2008; Garcia-Segura and Melcangi 2006). In CNS pathologies, astrocytes act as innate 
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immune cells that release several cytokines such as IL-6, IL-1ß, TNF-α, TGF-ß, IL-12, and IL-23 
and chemokines such as CCL2, CCL5, CXCL10, CXCL12, CXCL8, and CXCR5 which reactivate 
and recruit peripheral and resident immune cells to the site of the lesions. Like microglia, activated 
astrocytes can present antigens on MCH-II, in addition to their limited phagocytic function (Farina, 
Aloisi, and Meinl 2007). 
 
Figure 2: Morphological difference between protoplasmic and fibrous astrocytes. Scheme 
showing the morphological difference between protoplasmic astrocytes in the grey matter with 
their short fine branches (left side) and fibrous astrocytes in the white matter with their long fiber-
like processes (right side). Figure modified from (Ingo et al. 2018). 
1.2.  Glutamate uptake by astrocytes in the CNS 
This section is modified from my published review (Mahmoud et al. 2019). 
Although glutamate is the predominant excitatory neurotransmitter in the CNS (Fonnum 
1984), excess glutamate in the extracellular space is potentially toxic to neurons. Therefore, proper 
uptake of the excess synaptically-released glutamate from the extracellular space is indispensable 
and is performed by all cells in the CNS, including astrocytes, microglia, oligodendrocytes, and 
neurons (Mahmoud et al. 2019). Astrocytes are the principal cells responsible for glutamate uptake 
as they uptake about 90% of the released glutamate in the CNS (Eulenburg and Gomeza 2010; 
Lehre and Danbolt 1998). 
 
Gray matter White matter 
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1.2.1. Excitatory amino acid transporters (EAATs) 
The process of glutamate uptake is mediated by Na+-dependent glutamate uptake transporters, 
known as “excitatory amino acid transporters” (EAATs). Five isoforms of EAATs were identified 
so far, which are EAAT1 and EAAT2 in human and known in murine animals as glutamate-
aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1), respectively. Together 
EAAT1 and EAAT2 (GLAST and GLT-1) represent the majority of EAATs in the CNS, and they 
are expressed mainly by astrocytes. They uptake 80-90% of the total extracellular glutamate in the 
CNS (Anderson and Swanson 2000; Rose et al. 2018). Other isoforms include EAAT3, also known 
as excitatory amino acid carrier-1 (EAAC-1) and is expressed by neuronal cell bodies (Kanai and 
Hediger 1992), EAAT4 expressed by cerebellar Purkinje cells (Fairman et al. 1995), and EAAT5 
expressed by retinal glial cells (Arriza et al. 1997). 
1.2.2. Expression profile of EAAT1 and EAAT2 
EAAT1 and EAAT2 share the same structure with 65% similarity in their amino acid 
components (Gegelashvili and Schousboe 1997). They also have the same affinity to glutamate, 
and both can reduce extracellular glutamate to the same level (Owe, Marcaggi, and Attwell 2006). 
However, they differ in their anatomical distribution in the CNS. 
EAAT1 (GLAST) predominates in the CNS early after birth and is expressed by radial glial 
cells and immature astrocytes (Shibata et al. 1997). In adult CNS, EAAT1 (GLAST) predominates 
in the cerebellum, Müller glia in the retina, and cochlear glial cells in the inner ear, with limited 
expression in the forebrain. In adulthood, EAAT1 is expressed primarily by astrocytes, with some 
limited expression by microglia and oligodendrocytes (Schmitt et al. 1997). 
On the other hand, EAAT2 (GLT-1) represents the major EAAT in the adult CNS. It acquires 
its maximum expression within 3-5 weeks after birth. Unlike EAAT1, EAAT2 predominates in 
the forebrain and represents the main EAAT expressed by mature astrocytes in the CNS (Furuta, 
Rothstein, and Martin 1997; Ullensvang et al. 1997). 
In astrocytes, EAAT1 and EAAT2 are distributed in the form of clusters on the astrocytic 
processes in contact with active glutamatergic neurons (Zhou and Sutherland 2004). Moreover, 
the expression of both EAATs in astrocytes positively correlates with increased neuronal activity 
and its associated increased glutamate release (Poitry-Yamate, Vutskits, and Rauen 2002). 
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1.2.3. Evidence that EAAT2 and EAAT1 play the major role in glutamate uptake in the CNS 
Many experimental studies revealed the importance of EAAT-2 and EAAT-1 in the clearance 
of glutamate and prevention of its toxic effect on neurons. A study on astrocyte-deficient neuronal 
cultures reported a 100-fold increase in neuronal death mostly by glutamate toxicity (Rosenberg 
and Aizenman 1989). Other studies on preparations from the hippocampus and cerebellum showed 
that glutamate release from glutamatergic neurons induced glutamate transporter-associated 
currents in astrocytes, while no similar currents were detected in the excitatory neurons. These 
currents were abolished upon using D,L-threo-hydroxyaspartate (THA, a nonselective EAAT 
inhibitor) or dihydrokainate (DHK, a GLT-1 selective inhibitor) and in GLT-1 knockout mice 
(Clark and Barbour 1997; Kojima et al. 1999). 
In vivo studies on GLAST and GLT-1 double knockout mice revealed the development of 
neurodegeneration and progressive paralysis in these mice (Rothstein et al. 1996). Regarding the 
preferential importance of EAAT2 (GLT-1) in glutamate uptake, GLT-1 deficient mice, as well as 
mice lacking GLT-1 exclusively in astrocytes in a conditional knockout mouse model showed 
higher susceptibility to lethal seizures and loss of neurons (Petr et al. 2015; Tanaka et al. 1997), 
while GLAST-mutant mice were presented with cerebellar injury that resulted in defective motor 
coordination (Watase et al. 1998). By contrast, EAAT3 and EAAT4 knockout mice showed only 
minor neurological deficits (Huang and Bergles 2004; Peghini, Janzen, and Stoffel 1997), while 
no EAAT5 knockout animal model has yet been reported. 
1.2.4. Mechanism of glutamate uptake by EAATs 
When glutamate is released from the excitatory pre-synaptic neurons, a small percentage of 
this glutamate is taken up by the post-synaptic neurons (20% in the retina and cerebellar cortex, 
and a less percentage in the hippocampus), which is enough to perform the function of excitatory 
transmission. The majority of the released glutamate (80% or more) is taken up by EAAT1 and 
EAAT2 in astrocytes (Figure 3A) (Anderson and Swanson 2000; Mahmoud et al. 2019). 
Normally, glutamate concentration in the extracellular space is in the millimolar range (mM) 
while its concentration intracellularly is in micromolar quantities (µM). To achieve glutamate 
uptake against its concentration gradient, astrocytes consume high levels of intracellular adenosine 
triphosphate (ATP) generated by activation of the Na+/K+ ATPase in astrocytes (Pellerin and 
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Magistretti 1997); therefore, glutamate uptake is considered one of the highest energy-consuming 
processes in the CNS (Anderson and Swanson 2000).  
Several previous studies described the stoichiometry driving glutamate uptake by astrocytes 
to be achieved by the inward transport of 3 Na+ and 1 H+ ions with each glutamate anion taken up, 
in exchange with the outward transport of 2 K+ ions, with their concentration gradients (Levy, 
Warr, and Attwell 1998). This process is associated with what is called “uptake current”, which is 
a form of membrane depolarization in astrocytes caused by the inward transport of 2 additional 
positive ions (Bowman and Kimelberg 1984). 
 
Figure 3: Glutamate uptake and metabolism by astrocytes. (A) Glutamate uptake by 
astrocytes: only 20% of the released glutamate at the synapses is transferred to the post-synaptic 
neurons while the remaining extracellular glutamate (80%) is taken up by EAAT2 and EAAT1 in 
astrocytes. (B) Glutamate metabolism in astrocytes: glutamate can be metabolized by glutamine 
synthetase enzyme to glutamine which is released back to neurons or could be metabolized to α-
ketoglutarate to be used in ATP synthesis (Mahmoud et al. 2019). 
1.2.5. Metabolism of glutamate in astrocytes 
Glutamate metabolism in astrocytes follows one of two main pathways as shown in (Figure 
3B) (Mahmoud et al. 2019). Via glutamine synthetase enzyme, which is preferentially expressed 
Pre-synaptic neuron Post-synaptic neuron 
Synaptic cleft 
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in astrocytes, glutamate is converted to glutamine (Waniewski and Martin 1986), which is then 
released from astrocytes to the extracellular space by the Na+-dependent, electroneutral transporter 
SN1. Neurons then uptake glutamine from the extracellular space by their system A transporters 
and use it to resynthesize active neurotransmitters such as glutamate and GABA (Bröer et al. 2002; 
Bröer and Brookes 2001). Interestingly, activation of glutamine synthetase enzyme also has a 
detoxifying effect in the CNS, as it breaks down the blood-derived ammonia and brain ammonium 
(NH3/NH4+), keeping their concentrations less than 0.1 mM which protects against ammonium 
neurotoxicity (Marcaggi and Coles 2001). 
On the other side, glutamate can undergo oxidative degradation to produce α-ketoglutarate, 
which enters the tricarboxylic acid (TCA) cycle and represents a precursor for ATP production. 
Oxidative metabolism of glutamate is achieved either by deamination, via the mitochondrial 
enzyme, glutamate dehydrogenase (GDH), or by transamination using aspartate aminotransferase 
(AAT), alanine aminotransferase, and branched chain aminotransferase (BCAT) enzymes 
(McKenna et al. 2016). Curiously, the oxidative metabolism of glutamate results in the production 
of an excessive amount of energy that compensates for the ATP originally consumed in glutamate 
uptake (McKenna 2013). 
Depending on the concentration of glutamate in the extracellular space, glutamate metabolism 
is directed to one of these two pathways. If glutamate concentration is less than 0.2 mM, glutamate 
metabolism is directed towards glutamine synthesis to provide sufficient glutamate for neurons, 
while if it is more than 0.2 mM, glutamate is oxidatively degraded to maintain enough amount of 
ATP for glutamate uptake (McKenna et al. 1996). 
1.2.6. EAAT1 and EAAT2 regulation of expression 
Many factors regulate the expression of EAAT-1 and EAAT-2 under physiological and 
pathological conditions, at the level of the gene transcription and translation, post-translation, as 
well as the transporter activity. Here, we summarize the important factors at different levels. 
1.2.6.1. Transcriptional and translational modifications 
Glutamate concentration in the extracellular environment is one of the essential factors that 
influence the expression of glutamate transporters in astrocytes, as increased glutamate 
concentration was shown to upregulate GLAST protein expression and this effect was mediated 
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by activation of AMPA/Kainate receptors (Gegelashvili et al. 1996). Another study showed that 
glutamate also increases the cell surface expression of GLAST on astrocytes (Duan et al. 1999). 
Additionally, stimulation of different types of glutamate receptors in astrocytes could have 
either a positive or negative effect on the expression of the transporters. For example, activation 
of metabotropic glutamate receptors (mGluRs) group II upregulates GLAST mRNA and protein 
expression, while stimulation of group I mGluRs inhibits the expression of both GLAST and GLT-
1, and both mediate their effects via activation of ERK/PI3K/ NF-κB pathway (Lin et al. 2014). 
On the other hand, activation of ionotropic glutamate receptors (iGluRs) suppresses GLAST 
expression via activation of protein kinase C (PKC) signaling pathway (Lopez-Bayghen and 
Ortega 2004). 
Co-culturing astrocytes with neurons or neuron-conditioned medium (NCM) is a major factor 
that increases both GLT-1 and GLAST protein expressions and functional activities (Swanson et 
al. 1997). This effect could be attributed to the soluble molecules released from neurons to the 
culture medium such as pituitary adenylate cyclase-activating polypeptide (PACAP), whose 
effects on GLT-1 and GLAST were mediated by activation of PKC and protein kinase A (PKA) 
signaling pathways ( Figiel and Engele 2000). 
Various other factors mediate a positive effect on GLAST and/or GLT-1 mRNA and protein 
expression including hormones such as estrogen and glucocorticoids, growth factors such as 
epidermal growth factor (EGF), glial cell line-derived neurotrophic factor (GDNF), basic 
fibroblast growth factor (bFGF), and IGF-1, as well as treating astrocyte cultures with dibutyryl 
cyclic adenosine monophosphate (dbcAMP), ATP or adenosine. All these factors mediate their 
positive effects on glutamate transporters’ through activation of phosphoinositide 3-kinase (PI3K), 
nuclear factor-κB (NF-κB) or PKA signaling pathways (Chi-Castañeda, Suárez-Pozos, and Ortega 
2017; Gegelashvili and Schousboe 1997; Mahmoud et al. 2019; Sattler and Rothstein 2006). 
By contrast, other factors mediate a negative effect on the expression of one or both 
transporters involving, insulin hormone, endothelins, dopamine, and retinoic acid, in addition to 
many neuropathological conditions in the CNS such as brain ischemia and inflammatory 
conditions associated with the release of tumor necrosis factor-α (TNF-α). The repression of the 
transporters’ expression is achieved via the activation of PKA, NF-κB and YY1 pathways, and by 
suppressing JAK/STAT signaling pathway (Chi-Castañeda et al. 2017; Gegelashvili and 
Schousboe 1997; Mahmoud et al. 2019; Sattler and Rothstein 2006). 
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From the previous studies, it is obvious that depending on the interaction with environmental 
factors and other signaling pathways, activation of various singling pathways such as NF-κB, PKA 
or PKC could mediate either activation or inhibition of the expression of glutamate transporters in 
astrocytes (Mahmoud et al. 2019). 
1.2.6.2. Post-translational modifications and regulation of the transporter activity 
It is well-known that both GLAST and GLT-1 express potential sites of glycosylation. 
However, two independent studies revealed that glycosylation of both proteins during protein 
maturation does not have any effect on their protein trafficking to the cell surface or their functional 
activity (Conradt, Storck, and Stoffel 1995; Raunser et al. 2005). 
Another study in 2004 showed that the interaction with the membrane cholesterol is essential 
to stabilize EAAT2 protein on the cell membrane and maintain its glutamate uptake ability 
(Butchbach et al. 2004). 
Many contradictory reports were published regarding direct protein phosphorylation of 
GLAST and GLT-1 by PKC, PI3K or PKA, where different studies reported that they upregulate, 
have no effect or downregulate the movement of one or both transporter proteins to the astrocytic 
plasma membrane (Chi-Castañeda et al. 2017; Gegelashvili and Schousboe 1997; Mahmoud et al. 
2019; Sattler and Rothstein 2006). 
Moreover, various elements were shown to influence the glutamate uptake activity of one or 
both transporters. Arachidonic acid (AA) is one of these factors that is known to be a differential 
regulator, as it downregulates EAAT1 activity, while it upregulates glutamate uptake by EAAT2 
(Zerangue et al. 1995). In patients with Alzheimer’s disease (AD), Amyloid β-peptide was shown 
to inhibit the activity of glutamate transporters (Masliah et al. 1996), while in another study, it was 
shown to increase trafficking of GLAST protein to the cell membrane and enhance its functional 
activity (Ikegaya et al. 2002). 
One of the major cellular factors that inhibit the functional activity of glutamate transporters 
in astrocytes is oxidative stress. Two different reports showed that oxidative stress caused by 
hydrogen peroxide (H2O2) was associated with reduced glutamate uptake in astrocyte cultures due 
to direct oxidation of the sulfhydryl (SH) group of both transporter proteins (Trotti et al. 1997; 
Volterra et al. 1994). This negative effect of H2O2 was eliminated by treating the cultures with 
superoxide dismutase and catalase anti-oxidant enzymes (Sorg et al. 1997). In a recent study on 
13 
 
 
 
 
ascorbate (an antioxidant released by astrocytes during glutamate uptake and protects against 
glutamate neurotoxicity), ascorbate-deficient mice showed behavioral changes and a higher 
susceptibility to epilepsy than wild-type (WT) mice. In the same study, the authors demonstrated 
that ascorbate deficiency might explain the development of subclinical seizures in patients with 
AD (Mi et al. 2018). 
1.3.  Glutamate release by astrocytes in the CNS 
This section is modified from my published review (Mahmoud et al. 2019). 
In addition to glutamate uptake, recent studies revealed that astrocytes release traces of 
glutamate to the extracellular space, which modulates neuronal firing. The interest in astrocytic 
glutamate release started in 1990 when Cornell-Bell and colleagues reported that glutamate release 
from glutamatergic neurons induced intracellular Ca2+ ([Ca2+]i) level elevation in astrocytes 
(Cornell-Bell et al. 1990), followed by elevation of the [Ca2+]i in the adjacent neurons (Nedergaard 
1994). Later on, it was shown that this high [Ca2+]i level in astrocytes evoked glutamate release 
from astrocytes (Parpura et al. 1994). 
1.3.1. Functions of astrocytic glutamate release 
The released glutamate from astrocytes plays many vital roles that modulate neuronal firing 
and regulate the synaptic activity (Hamilton and Attwell 2010; Mahmoud et al. 2019).  These roles 
include: 
Synchronization and strengthening of the firing of excitatory neurons. The released glutamate 
from glutamatergic neurons stimulates type I and V mGluRs in astrocytes, which induce elevation 
of [Ca2+]i level in astrocytes, that in turn evokes glutamate release. The released glutamate from 
astrocytes activates group I mGluRs or N-methyl-D-aspartate (NMDA) receptors in the adjacent 
neurons which increases the amount of glutamate release from the excitatory neurons and 
generates neuronal slow inward currents that are thought to synchronize their firings (Fellin et al. 
2004; Jourdain et al. 2007). 
Potentiation of neuronal inhibition. GABA release from the inhibitory neurons stimulates 
GABAB receptors in astrocytes, which triggers [Ca2+]i  rise and induces glutamate release from 
astrocytes. Through activation of neuronal presynaptic iGluRs, the released glutamate from 
astrocytes increases GABA release from the adjacent inhibitory neurons (Kang et al. 1998). 
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Potentiation of the transient hetero-synaptic inhibition in the hippocampus. The released 
glutamate from the excitatory afferents to CA1 pyramidal cells stimulates interneurons to release 
GABA. GABA activates GABAB receptors in astrocytes, which elevates [Ca2+]i  and triggers 
glutamate release from astrocytes. This glutamate acts on presynaptic Group I and III mGluRs in 
the adjacent afferents to inhibit glutamate release (Andersson, Blomstrand, and Hanse 2007).  
1.3.2. Mechanisms of astrocytic glutamate release 
Glutamate release by astrocytes is mediated primarily by Ca2+-dependent exocytosis; 
however, several other Ca2+-dependent and Ca2+-independent mechanisms were shown to be 
implicated in astrocytic glutamate release in healthy CNS and pathological conditions (Mahmoud 
et al. 2019; Malarkey and Parpura 2008). In this context, we summarize these mechanisms and 
their contribution to glutamate release from astrocytes (Figure 4) (Mahmoud et al. 2019). 
1.3.2.1. Ca2+-mediated glutamate exocytosis 
Ca2+-mediated exocytosis is yet considered the principal mechanism responsible for glutamate 
release by astrocytes in the healthy CNS (Figure 4A). Similar to neurons, astrocytes express all 
the machinery necessary for glutamate exocytosis. In neurons, glutamate is packed inside small 
intracellular vesicles, from which glutamate is released to the synaptic cleft. Electron microscopic 
visualization of the hippocampal astrocytes revealed the presence of small intracellular vesicles (~ 
30 nm), like those in neurons (Bezzi et al. 2004). Another imaging study demonstrated that rat 
hippocampal astrocytes contain large intracellular vesicles (~ 300 nm) containing glutamate, from 
which only 10% of their glutamate content is released in a “kiss and run” mechanism (Chen et al. 
2005).  
In addition, the small intracellular vesicles in astrocytes express the vesicular glutamate 
transporters 1 and 2 (VGLUT1 and VGLUT2), like those expressed by neurons. These transporters 
are localized in astrocytes in contact with presynaptic neurons expressing NMDA receptors. The 
function of these transporters is to transfer glutamate from the cytosol to the vesicles to be ready 
for exocytosis. The function of both transporters in astrocytes, as well as in neurons is derived by 
the voltage and proton gradient generated by the vacuolar (H+) ATPase across the vesicular 
membrane (Montana et al. 2004).  
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Glutamate exocytosis from neurons occurs in response to [Ca2+]i elevation caused by 
extracellular Ca2+ entry via the voltage-gated Ca2+ channels. This rise in the [Ca2+]i is sensed by 
the Ca2+ sensor, synaptotagmin 1, expressed by neurons. Unlike neurons, the main source of [Ca2+]i 
elevation in astrocytes comes from the intracellular Ca2+ stores.  Stimulation of the G protein-
coupled receptors (GPCRs) in astrocytes activates inositol-1,4,5-trisphosphate (IP3), which in turn 
triggers Ca2+ release from the endoplasmic reticulum (ER) (Hua et al. 2004). Mitochondrial Ca2+ 
also plays a role in astrocytic glutamate release by modulating cytoplasmic Ca2+ dynamics (Reyes 
and Parpura 2008). By contrast, extracellular Ca2+ plays a minor role in astrocytic glutamate 
exocytosis (Hua et al. 2004). Further studies demonstrated that astrocytes express synaptotagmin 
4, 7 or 11 (analogs of synaptotagmin 1 in neurons) (Wang et al. 2003). To trigger glutamate 
exocytosis from astrocytes, the [Ca2+]i level should reach approximately 250–350 nM (Parpura and 
Haydon 2000).   
To complete the process of exocytosis in neurons, in response to the [Ca2+]i elevation, the 
vesicle fusion protein, vesicle-associated membrane protein 2 (VAMP2) attaches to the cell 
membrane fusion proteins, Syntaxin and synaptosomal-associated protein 25 (SNAP25) to form 
soluble N-ethylmaleimide-sensitive factor attachment protein receptors complex (SNARE 
complex) (Jahn and Scheller 2006). Similar fusion proteins are expressed in astrocytes to achieve 
glutamate exocytosis. Astrocytes express the vesicle fusion protein VAMP2 or its analog VAMP3 
(Bezzi et al. 2004), and the cell membrane fusion proteins, Syntaxin and SNAP23 (analog of 
SNAP25 in neurons) (Hepp et al. 1999; Parpura et al. 1995). Therefore, they have the ability to 
form a SNARE complex, as do neurons, resulting in glutamate release from the vesicles to the 
extracellular space. 
1.3.2.2. Bestrophin-1 and TREK-1 channel-mediated glutamate release 
A newly identified Ca2+-mediated glutamate release channel is called Bestrophin-1 (Best-1 
channel) (Figure 4B). Glutamate release through Best-1 channels also occurs in response to GPCR 
stimulation in astrocytes, which triggers a rise in the [Ca2+]i that induces glutamate release. 
However, it is not yet identified whether these channels can directly sense the rise in [Ca2+]i or 
through a Ca2+ sensor. The released glutamate via Best-1 channels targets the synaptic NMDA 
receptors in neurons and generates inward neuronal currents that are much slower than those 
generated by glutamate exocytosis. TREK-1 channels are other newly identified channels that 
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release glutamate in a Ca2+-independent mechanism (Figure 4C). They are K+ channels that allow 
the outward transport of glutamate in exchange with K+. The released glutamate via TREK-1 
channels targets mGluRs in neurons and generates neuronal currents that are very rapid compared 
to those generated by Best-1-mediated glutamate release (Han et al. 2013; Woo et al. 2012). 
 
Figure 4: Mechanisms of glutamate release by astrocytes. (A) Ca2+-mediated exocytosis: 
astrocytes express VGLUT1 and VGLUT2, which transport glutamate to the intracellular 
vesicles. Stimulation of the GPCRs in astrocytes results in Ca2+ release from the ER in response 
to IP3 formation. Sensing the intracellular Ca2+ elevation by synaptotagmin 4, 7 or 11, induces 
fusion of the vesicular protein VAMP2 or VAMP3 with the cell membrane fusion proteins 
Syntaxin and SNAP23 to form SNARE complex, resulting in glutamate release. (B) Best-1 
channels: glutamate release occurs in a Ca2+-dependent mechanism following GPCR stimulation. 
(C) TREK-1 channels: glutamate is released in exchange with K+ uptake. (D) P2X7 receptors: 
glutamate release occurs in exchange with ATP uptake. (E) Cystine/glutamate antiporters: 
glutamate is released in exchange with cystine uptake. (F) Reversal of uptake transporters: in 
severe ischemia or stroke. (G) Gap junction hemichannels: formed by connexin and pannexin 
proteins. (H) Volume-regulated anion channels (VRACs): as in the case of brain edema 
(Mahmoud et al. 2019). 
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1.3.2.3. Glutamate release through P2X7 receptors 
P2X Purinoceptor 7 (P2X7) receptors are ATP uptake receptors. When these receptors are 
activated in astrocytes in vitro, they allow the release of glutamate in exchange with the inward 
transport of ATP (Duan et al. 2003) (Figure 4D). However, the contribution of these receptors to 
the glutamate release in vivo is still unclear. 
1.3.2.4. Cystine/glutamate antiporters 
They are Cl- dependent cystine uptake transporters that allow the outward transport of 
glutamate in exchange with the cystine uptake (Figure 4E). In two different studies, activating 
these transporters in the cerebellum and rat striatum induced glutamate release from astrocytes and 
generated inward currents in the adjacent neurons (Baker et al. 2002; Warr, Takahashi, and Attwell 
1999). In a third study, adding cystine to the acutely-cut brain slices increased the level of the 
extracellular glutamate (Moran et al. 2005). 
1.3.2.5. Reversal of glutamate uptake transporters 
This mechanism of glutamate release occurs only in pathological conditions. In case of 
reversal of the driving forces of glutamate uptake such as reversal of intracellular and extracellular 
Na+/K+ ratio or ATP depletion as in case of severe ischemia, glutamate transporters lose their 
function of glutamate uptake, and they may reverse, resulting in glutamate release via a Ca2+-
independent mechanism (Grewer et al. 2008; Phillis and O’Regan 1996; Rossi, Oshima, and 
Attwell 2000) (Figure 4F). 
1.3.2.6. Gap junction hemichannels 
The gap junctions connecting astrocytes are formed by Connexin and Pannexin proteins 
arranged in the form of hemichannels. Activation of these hemichannels in vitro in ischemic 
astrocytes results in the release of glutamate from the cytoplasm to the extracellular space in a 
Ca2+-independent mechanism (Ye et al. 2003) (Figure 4G).  
1.3.2.7. Volume-regulated anion channels (VRACs) 
Glutamate release through the VRACs was reported to occur in pathological conditions, in 
vitro in swollen astrocytes, and in vivo in brain edema and stroke. In these conditions, VRACs 
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open and allow the outward transport of glutamate (Kimelberg et al. 1990; Seki et al. 1999) (Figure 
4H). However, it is not yet known whether this mechanism of glutamate release is Ca2+-dependent 
or independent (O’Connor and Kimelberg 1993). 
1.4.  Glutamate excitotoxicity 
This section is modified from my published review (Mahmoud et al. 2019). 
Under physiological conditions, glutamate concentration in the extracellular space of the CNS 
must be maintained at very low levels to prevent overstimulation of glutamate receptors in neurons 
and its subsequent neuronal death. 
Under pathological conditions, the pathogenesis of almost all CNS disorders is associated with 
inflammation. Astrocytes respond to inflammation by undergoing molecular, morphological, and 
functional changes in a process known as “reactive astrogliosis”. Reactive astrocytes may lose 
some of their vital functions in the CNS or acquire many harmful effects that exacerbate the 
inflammatory response and delay the process of recovery. Reactive astrogliosis may be associated 
with loss of the astrocytic function of glutamate uptake and/or excessive glutamate release, which 
lead to accumulation of glutamate in the extracellular space and predispose to glutamate 
excitotoxicity (Sofroniew and Vinters 2010). 
Glutamate excitotoxicity is defined as “the process by which neuronal death, by apoptosis or 
necrosis, occurs as a result of excessive or prolonged exposure of neurons to the extracellular 
glutamate” (Mahmoud et al. 2019). 
1.4.1. CNS disorders associated with glutamate excitotoxicity 
Glutamate excitotoxicity caused by reduced astrocytic glutamate uptake occurs in many CNS 
diseases such as CNS trauma. The expression of both glutamate transporters, EAAT1 and EAAT2, 
is significantly reduced in astrocytes for up to 7 days post-trauma (Landeghem et al. 2006). The 
same effect on the transporters occurs following CNS infection with human immunodeficiency 
virus (HIV) (Vesce et al. 1997). 
Neurodegenerative diseases are commonly associated with impaired glutamate uptake. In 
amyotrophic lateral sclerosis (ALS), the affected patients suffer from loss of functions of the motor 
neurons caused by loss of EAAT2 expression in the spinal cord astrocytes (Rothstein et al. 1995). 
Interestingly, β-lactam antibiotics were neuroprotective in the animal models of ALS, as β-lactam 
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upregulates the expression and the functional activity of GLT-1 (EAAT2) in the CNS of these 
animal models (Rothstein et al. 2005). Inhibition of glutamate uptake may also be involved in other 
neurodegenerative diseases such as Parkinson’s disease (PD), AD, Huntington’s disease and 
epilepsy (Sheldon and Robinson 2007).  
Many in vitro and in vivo studies demonstrated that glutamate excitotoxicity is implicated in 
the pathogenesis of multiple sclerosis (MS), an autoimmune disease affecting the CNS. Incubating 
astrocytes in vitro with MOG-activated T-cells (myelin-specific T-cells) induced marked reduction 
of GLAST expression in astrocytes, and this effect was mediated by T-cell-released TNF-α (Korn, 
Magnus, and Jung 2005). In vivo studies on experimental autoimmune encephalomyelitis (EAE, a 
mouse model of MS) revealed that reduced glutamate uptake in the CNS resulted in the death of 
neurons and oligodendrocytes, and exacerbated the process of demyelination (Pitt, Werner, and 
Raine 2000). Moreover, several studies on human MS revealed that glutamate excitotoxicity is 
involved in the pathogenesis of the disease (Werner, Pitt, and Raine 2001). Therefore, riluzole, an 
anti-glutamatergic drug, is now in clinical trials for the treatment of early onset MS (onset of less 
than one year) (Waubant et al. 2014).  
Total failure of glutamate uptake occurs in CNS disorders associated with reversal or depletion 
of the driving forces of glutamate uptake such as the depletion of intracellular ATP that may occur 
in brain ischemia or stroke (Grewer et al. 2008; Phillis and O’Regan 1996; Rossi et al. 2000). 
Reversal of the Na+/K+ ratio is another example that occurs in hepatic encephalopathy, in which 
intracellular Na+ is markedly augmented as a result of ammonium toxicity (Kelly et al. 2009). In 
addition to the glutamate uptake failure in these diseases, reversal of glutamate uptake transporters 
also may occur, as previously described, resulting in glutamate release, which exacerbates the 
glutamate excitotoxicity (Grewer et al. 2008; Phillis and O’Regan 1996; Rossi et al. 2000). 
Glutamate excitotoxicity caused by abnormal excessive release of glutamate from astrocytes 
commonly occurs in CNS disorders accompanied by increased release of the inflammatory 
mediators, TNF-α and prostaglandin E (Bezzi et al. 1998, 2001). These two mediators trigger a 
rise in the [Ca2+]i level in astrocytes, which in turn enhances glutamate exocytosis, as occurs in the 
CNS infection with HIV, brain stroke, AD and MS (Hamilton and Attwell 2010). 
Various studies on neuro-psychiatric disorders demonstrated that combined dysregulation of 
both glutamate uptake and release by astrocytes contributes to the development of mood disorders 
and depression-like symptoms in animal models. Also, it was shown to be implicated in the 
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pathogenesis of the major depressive disorder (MDD) and schizophrenia in human (Bechtholt-
Gompf et al. 2010; Haroon, Miller, and Sanacora 2017; Takahashi, Foster, and Lin 2015). 
Therefore, riluzole (the anti-glutamatergic drug) is used as an anti-depressant treatment for patients 
with MDD (Sanacora et al. 2007; Zarate et al. 2004). 
1.4.2. Molecular mechanisms of glutamate excitotoxicity 
Hyperstimulation of neuronal glutamate receptors results in the activation of several molecular 
pathways that interact synergistically and lead eventually to neuronal death. Here, we summarize 
the key molecular mechanisms involved in the pathogenesis of glutamate excitotoxicity (Figure 
5) (Mahmoud et al. 2019). 
 
Figure 5: Molecular mechanisms of glutamate excitotoxicity. (A) Excess extracellular 
glutamate triggers hyperexcitation of neuronal ionotropic glutamate receptors and metabotropic 
receptors, resulting in augmentation of the [Ca2+]i level caused by excess Ca2+ entry via ionic 
channels and excess Ca2+ release from the ER, respectively. This elevation in the [Ca2+]i level 
represents a signal for apoptosis. (B) The rapid influx of Na+ and Cl- ions, and water to neurons 
results in rupture of the neuronal plasma membrane. (C) Oxidative stress caused by excess ROS, 
RNS, and the deficiency of antioxidants induces damage to the cellular proteins and nucleic acid, 
which in turn triggers apoptosis. (D) Excessive Ca2+ entry into the mitochondria (D1) and 
mitochondrial overstimulation by oxidative stress (D2) result in the opening of mitochondrial 
transition pores and release of Cytochrome C which initiate the apoptotic cascades (Mahmoud et 
al. 2019). 
First, excess glutamate in the extracellular space, caused by reduced glutamate uptake or 
increased glutamate release by astrocytes induces hyperstimulation of glutamate ionotropic 
receptors in neurons, which are NMDA, α-amino-3-hydroxy-5-methylisoxazole-4-propionate 
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(AMPA), and kainic acid (KA) receptors. The stimulation of which triggers Ca2+ entry through the 
voltage-gated anion channels in neurons. Excess glutamate also hyperstimulates group I and V 
mGluRs in neurons, which in turn triggers the formation of IP3 and Ca2+ release from the ER. The 
resulting high [Ca2+]i level will raise the Ca2+ concentration in the Ca2+-sensitive organelles, 
mitochondria and ER, which represents the first signal to induce neuronal apoptosis. Also, the 
elevated [Ca2+]i level activates apoptotic proteases such as calcineurin and calpain to induce 
apoptosis (Dong, Wang, and Qin 2009; Mahmoud et al. 2019; Wang and Qin 2010). 
Second, the excessive Ca2+ entry mediated by hyperstimulation of NMDA receptors causes 
excessive influx of water and ions such as Na+ and Cl- into neurons, which in turn induces acute 
rupture of the neuronal plasma membrane and neuronal death by necrosis (Dong et al. 2009; 
Mahmoud et al. 2019; Wang and Qin 2010). 
Third, the pathogenesis of glutamate excitotoxicity is often associated with oxidative stress, 
caused by excessive production of reactive oxygen species (ROS), especially superoxide (O2-) and 
hydroxyl radicals (OH.). Neurodegenerative diseases also could be associated with reduced levels 
of antioxidants. Excessive reactive nitrogen species (RNS) also play a role in oxidative stress. 
Excess Ca2+ entry via the cation channels mediated by NMDA receptor stimulation activates nitric 
oxide synthetase (NOS) enzyme that synthesizes NO. NO interacts with O2- to produce 
peroxynitrite (OONO-). The resulting oxidative stress causes damage to the intracellular proteins, 
nucleic acid, lipids, and other molecules, resulting in activation of the intracellular apoptotic 
pathways (Dong et al. 2009; Mahmoud et al. 2019; Wang and Qin 2010). 
Finally, Excessive mitochondrial stimulation by the high [Ca2+]i levels and oxidative stress 
results in the opening of mitochondrial permeability transition pores and release of pro-apoptotic 
molecules into the cytosol such as cytochrome C, which activate the mitochondria-mediated 
apoptotic pathways (Dong et al. 2009; Mahmoud et al. 2019; Wang and Qin 2010). 
1.5.  Pattern recognition receptors (PRRs) 
PRRs are groups of receptors expressed mainly by innate immune cells. They detect unique 
molecular structures of conserved pathogen-associated molecular patterns (PAMPs) in the 
structure of the microorganisms that are important for their physiology such as the cell membrane 
and the nuclei. They can also recognize patterns from the released molecules of tissue damage or 
stress, known as damage-associated molecular patterns (DAMPs) such as heat shock proteins 
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(HSP), damaged nucleic acid, and ATP. Upon recognition of PAMPs or DAMPs, PRRs initialize 
series of signaling cascades that lead to the activation of transcription factors such as NF-κB and 
MAPK, and production of chemokines and cytokines that recruit and activate other innate and 
adaptive immune cells (Mogensen 2009). PRRs are divided into 4 groups of receptors which are 
situated either on the cell membrane or intracellularly. These groups are: 
1.5.1. Toll-like receptors (TLRs) 
TLRs are a big group of PRRs that is expressed in most of the cell types. 10 subtypes of TLRs 
were identified, among which TLRs 1, 2, 4, 5, 6, and 10 are transmembranous and can recognize 
extracellular molecules such as bacterial lipopolysaccharide (LPS) and flagellin. Once the surface 
TLRs become activated, they activate NF-κB transcription factor, that leads to the production of 
pro-inflammatory mediators including chemokines, cytokines, and ROS that activate 
phagocytosis, recruit more neutrophils and macrophages to the site of infection, activate cells of 
the adaptive immune response, and accelerate clearance of the microorganism. TLRs 3, 7, 8, and 
9 are expressed in the endosomes and can recognize virus single-stranded RNA (ssRNA) or 
double-stranded RNA (dsRNA), and unmethylated CpG DNA. When endosomal TLRs get 
activated, they activate interferon regulatory factors (IRFs), which induce the production of type I 
interferon (IFN-α and IFN-β) to eradicate the viral infection (Dowling and Mansell 2016). 
1.5.2. C-type lectin receptors (CLRs) 
This group of PRRs is expressed on the cell surface and can recognize carbohydrate structures 
of the microorganism such as mannose, fucose, and glucan. Recognition of these molecules results 
in internalization and phagocytosis of the pathogen followed by antigen presentation. Therefore, 
CLRs are expressed mainly in the antigen-presenting cells (APCs) such as monocytes, 
macrophages, and dendritic cells (DCs). Furthermore, activation of the mannose-binding lectins 
activates the complement system, which can fight the infection in several ways; direct lysis of the 
pathogen, generation of anaphylatoxins, and opsonization of the infected cells (Dunkelberger and 
Song 2010). 
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1.5.3. RIG-I-like receptors (RLRs) 
RLRs are intracellular PRRs expressed in the cytosol of immune and non-immune cells. 3 
members of this group were identified, which are RIG-1, melanoma differentiation associated gene 
5 (MDA5), and laboratory of genetics and physiology 2 (LGP2). They recognize viral RNA, and 
upon activation, RLRs activate the antiviral signaling pathways to produce type I interferons 
(Sparrer and Gack 2015). 
1.5.4. NOD-like receptors (NLRs) 
They are also known as the nucleotide-binding and leucine-rich repeat-containing proteins 
(NLRs). NLRs are expressed in the cytoplasm of immune cells such as macrophages, dendritic 
cells, and neutrophils, as well as non-immune cells. They can sense a wide variety of PAMPs such 
as bacterial peptidoglycans and viral RNA, in addition to DAMPs from uric acid, ATP, nucleic 
acid proteins, ROS, alterations in osmolarity, and polysaccharides (Kumar, Kawai, and Akira 
2011). The importance of NLRs in the host defense is highlighted by being evolutionary conserved 
across different species including plants and mammals (Jha and Pan-Yun Ting 2015). Also, genetic 
mutations in several members of NLRs are associated with the development of many human 
diseases such as Cryopyrin-Associated Periodic Syndromes (CAPS), which are auto-immune 
syndromes associated with a mutation in Nlrp3 gene (Lequerre et al. 2006). Mutations in Nlrp1 
were shown to be associated with vitiligo (Jin et al. 2007), and mutations in the NOD2 gene is 
associated with Blau Syndrome (Miceli-Richard et al. 2001).  
According to their structure, NLR family members contain 3 characteristic domains (Figure 
6A), the C-terminal leucine-rich repeat (LRR), which is the ligand binding domain, the central 
nucleotide binding domain (NBD), which is responsible for oligomerization of the protein, and the 
N-terminal domain, which is the effector domain (Allen 2014; Gharagozloo et al. 2018). Till now, 
23 members of the NLR family were identified in human, and more than 34 were identified in 
mice (Franchi et al. 2009). According to the difference in their N-terminal domain structure, NLRs 
are classified into 4 sub-categories (Figure 6B), (1) NLRA, including only one family member, 
Class II transactivator (CIITA), in which the effector domain is the acidic transactivation (AD) 
domain, (2) NLRB, possesses baculovirus inhibitor of apoptosis protein repeat (BIR), (3) NLRC, 
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contains caspase recruitment domain (CARD) or unknown (X) domain, and (4) NLRP, containing 
pyrin domain (PYD) (Barbé, Douglas, and Saleh 2014; Gharagozloo et al. 2018). 
 
Figure 6: Structure of NLRs. (A) NLR proteins contain 3 domains, the C-terminal LRR, which 
is the ligand sensing domain, the central NBD, and the N-terminal functional domain. (B) 
According to the structure of the functional domain, NLRs contain 4 subgroups: NLRA with an 
AD domain, NLRB with a BIR domain, NLRC with a CARD or X (unknown) domains. One 
member of the NLRC group, NLRX1, contains a Mito sequence, which is the mitochondrial 
addressing sequence that localizes the protein to the mitochondria, and NLRP with a PYD domain 
(Gharagozloo et al. 2018). 
According to their functions, NLRs are classified into 2 main categories, the inflammasome 
and the non-inflammasome NLRs (Figure 7). The inflammasome NLRs are proteins that can 
assemble into large cytoplasmic multiprotein complexes such as NLRP1, NLRP3, NLRC4, 
NLRC5, and NLRP12. They cleave pro-caspase 1 to active caspase-1, which in turn cleaves pro-
IL-1β and pro-IL-18 into the active pro-inflammatory cytokines IL-1β and IL-18. On the other 
side, the non-inflammasome NLRs contains 2 further subgroups. The first one contains the 
transcriptional co-activators, CIITA and NLRC5, which are the master regulators of MHC-II and 
MHC-I expressions, respectively. The second subgroup contains the regulators of NF-κB 
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activation, which involve those proteins that activate NF-κB, such as NOD1 and NOD2, and result 
in the production of pro-inflammatory mediators, and other members that inhibit NF-κB such as 
NLRX1 and NLRP12, thus suppressing the inflammatory response. It is noteworthy to say that 2 
NLR family members, NLRP12 and NLRC5, could have either inflammasome or non-
inflammasome functions in different contexts according to the cell type and the stimulator of 
inflammation (Gharagozloo et al. 2018). 
 
Figure 7: Functional classification of NLRs. Functionally, NLRs could be categorized into the 
inflammasome or non-inflammasome forming members. The inflammasome proteins are those 
that activate caspase-1 and result in the release of IL-1β and IL-18. The non-inflammasome 
members could be either transcription factors that regulate the expression of MHC-I and MHC-
II, or the regulators of NF-κB, which are either positive or negative regulators of inflammation 
(Gharagozloo et al. 2018). 
1.5.4.1. NOD-like receptor X1 (NLRX1) 
NLRX1 is a recently discovered member of the non-inflammasome NLRs that inhibit NF-κB. 
It is ubiquitously expressed, and unlike other members of NLRs, NLRX1 possesses a 
mitochondrial addressing sequence in its N-terminal domain that localizes the protein to the 
mitochondria (Moore et al. 2008). However, its exact location in the mitochondria is still unclear. 
A study in 2008 demonstrated that NLRX1 is located in the outer mitochondrial membrane (Moore 
et al. 2008) while 3 other more recent studies showed that NLRX1 is situated in the mitochondrial 
matrix (Arnoult et al. 2009; Rhee et al. 2013; Singh et al. 2018).  
Regarding the role of NLRX1 in the regulation of anti-microbial immune response, many 
contradictory studies were published using different models of infection. Early in 2008, Tattoli et 
al. reported that NLRX1 enhanced ROS production in the cells treated with TNF-α, shigella 
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infection and dsRNA, and this high level of ROS activated NF-κB and JUN amino-terminal 
kinases-dependent (JNK) signaling pathways (Tattoli et al. 2008). By contrast, several subsequent 
studies provided evidence that NLRX1 is a negative regulator for NF-κB. After treatment with 
LPS in vivo and in vitro, NLRX1 was shown to inhibit TLR-mediated activation of NF-κB, by 
interacting with TRAF6 in its canonical pathway (Allen et al. 2011; Xia et al. 2011), and by 
inhibiting phosphorylation of IKKα and IKKβ, which results in the suppression of NF-κB pathway 
(Xia et al. 2011). 
During viral infections, viral PAMPs are recognized by RIG-1 protein in the cytoplasm, which 
in turn activates the mitochondrial antiviral signaling (MAVS) pathway. The activation of which, 
in turn, activates the interferon regulatory factors (IRFs) that induce the production of type I 
interferons to eliminate the viral infection. In 2 studies done by Moore et al. and Allen et al., 
NLRX1 was shown to interact with MAVS adaptor in the outer mitochondrial membrane and 
inhibits RIG-1-MAVS signaling pathway, which inhibits the production of IFN type I (Allen et al. 
2011; Moore et al. 2008). In a recent study in 2019, Song et al. demonstrated that the central NBD 
(NACHT) of NLRX1 protein is necessary for its interaction with MAVS to suppress the antiviral 
immune response (Song et al. 2019). 
In another study, Lei et al. showed that NLRX1 interacts with Tu translation elongation factor 
(TUFM) in the mitochondrial matrix, which promotes autophagy during viral infection; therefore, 
it inhibits type I IFN production (Lei et al. 2012). Interestingly, another group confirmed the role 
of NLRX1 in promoting autophagy in macrophages by the same mechanism in a model of fungal 
infection by Histoplasma capsulatum (Huang et al. 2018). However, in a recent study, NLRX1 
was reported to suppress the invasion and autophagy of group A streptococcal infection, by 
interacting with Beclin-1 and UVRAG members of Beclin-1 complex, that eventually inhibits 
autophagosome and autolysosome formation (Aikawa et al. 2018). From the previous reports, it is 
clear that NLRX1 can mediate a positive or negative effect on the anti-microbial immune response 
depending on the experimental conditions and the nature of the microorganism. 
Regarding sterile inflammation, NLRX1 was shown to inhibit inflammatory bowel disease 
(IBD) in mice and decrease its associated colonic lesions and inflammatory mediators (Leber et 
al. 2018). NLRX1 also protects against colitis induced by dextran sodium sulfate (Leber et al. 
2017) and inhibits colitis-associated cancer in mice by suppressing NF-κB pathway (Tattoli et al. 
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2016). In an in vitro model of osteoarthritis, Ma et al. reported that NLRX1 overexpression inhibits 
LPS-induced apoptosis and inflammation in chondrocytes also by repressing NF-κB (Ma et al. 
2019). 
In the CNS, Eitas et al. showed that NLRX1 protects against the development of EAE (a 
mouse model of MS). CNS tissue staining showed more tissue damage with enhanced 
demyelination in the spinal cord of Nlrx1 knockout (Nlrx1-/-) mice relative to WT. Flow cytometry 
analysis indicated that there was a higher infiltration of macrophages/microglia and T-cells into 
the spinal cord tissue of Nlrx1-/- mice, associated with increased mRNA expression of pro-
inflammatory cytokines Tgfb-1, Ifn-ɣ, Il-17a, Il-17f, and Il-22. Nlrx1-/- mice also showed enhanced 
microglial activation and higher inflammatory response than WT mice, evidenced by increased 
expression of MCH-II and increased production of the pro-inflammatory mediators, IL-6 and 
CCL2 (Eitas et al. 2014). 
In a mouse model of traumatic brain injury, Nlrx1-/- mice had larger brain lesions and more 
motor neurological deficits following a controlled cortical impact (CCI) injury compared to WT 
mice. At the cellular level, Nlrx1-/- mice were associated with higher proliferation and infiltration 
of microglia at the lesion sites. NF-κB signaling was also upregulated in the microglia of Nlrx1-/- 
mice compared to WT. NLRX1 also protected neurons from cell death following oxidative stress 
in vitro (Theus et al. 2017). These data suggest that NLRX1 negatively regulates sterile 
inflammation by inhibiting NF-κB activation. 
Concerning the role of NLRX1 in human diseases, there is only one published study linking 
a mutation in nlrx1 to chronic hepatitis B (CHB) virus infection. The authors discovered a missense 
mutation in the LRR of nlrx1 associated with increased susceptibility to CHB infection in human 
patients, based on a study involved 50 CHB patients versus 40 controls (Zhao et al. 2012). 
Additionally, the level of the mRNA or protein expression of NLRX1 is altered in various 
human diseases. In a study published in 2015, by Kang and colleges, the authors revealed that the 
mRNA expression of nlrx1 is significantly reduced in the lung tissues of patients with chronic 
obstructive pulmonary disease (COPD) relative to controls. This nlrx1 suppression positively 
correlated with the disease severity and negatively correlated with the pulmonary function (Kang 
et al. 2015). In another study in 2017, Stokman et al. examined NLRX1 protein expression using 
IHC, in renal biopsies from patients with acute tubular necrosis (ATN) and acute cellular rejection 
(ACR). NLRX1 was also significantly reduced in both ATN and ACR compared to healthy 
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controls (Stokman et al. 2017). In the CNS, there is only one publication evaluated the gene 
expression of nlrx1 by microarray meta-analysis in patients following ruptured brain aneurysms. 
In these patients, nlrx1 expression was markedly downregulated relative to controls (Theus et al. 
2017). 
Due to its localization to the mitochondria, NLRX1 regulates mitochondrial dynamics and 
functional activities. In a previous publication from our group, we used NLRX1 Knock-In (KI) 
and Knock-Down (KD) N2A neuroblastoma cell lines, and cells transfected with scrambled 
shRNA (Sc) as controls. We showed that NLRX1 inhibits neuronal death and shifts neuronal death 
from necrosis to apoptosis following rotenone treatment. Also, we showed that NLRX1 enhances 
mitochondrial fission in neurons by interacting with the fission protein, DRP1 (Imbeault et al. 
2014). In another study, NLRX1 inhibited apoptosis of macrophages following influenza A virus 
infection (Jaworska et al. 2014). However, in case of cell stress or glucose deprivation, NLRX1 
enhances the intrinsic apoptotic pathway (Soares et al. 2014). Moreover, NLRX1 inhibits oxidative 
stress and apoptosis while it enhances mitochondrial respiration and ATP production in renal 
tubular epithelial cells in a model of ischemia-reperfusion injury (Stokman et al. 2017), and in 
human breast cancer tissue (Singh et al. 2019). Taken together, these reports suggest that NLRX1 
enhances mitochondrial fission, respiration, and ATP production. On the other hand, it inhibits 
oxidative stress and cell death and directs cell death towards apoptosis instead of necrosis in case 
of cellular stress. 
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2. HYPOTHESIS AND OBJECTIVES 
 
We hypothesized that NLRX1 enhances glutamate uptake and inhibits glutamate release by 
astrocytes via enhancing mitochondrial functions. 
 
To test our hypothesis, we investigated the role of NLRX1 in: 
1- Glutamate uptake by astrocytes 
2- Glutamate release by astrocytes 
3- Mitochondrial functions in astrocytes including: 
• ATP production 
• Oxidative stress 
• Ca2+ homeostasis 
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Résumé 
L'absorption de glutamate provenant de l'espace extracellulaire et la libération de glutamate pour 
les neurones sont deux importants processus pris en charge par les astrocytes du système nerveux 
central (SNC). L’absorption du glutamate protège contre l'excitotoxicité causée par le glutamate 
tandis que la libération du glutamate pour les neurones renforce la décharge neuronale. En cas 
d'inflammation du SNC, les astrocytes peuvent perdre l'une de ces fonctions, voire les deux, ce qui 
entraîne une accumulation du glutamate extracellulaire. Cette accumulation conduit à une mort 
neuronale excitotoxique ce qui aggrave à son tour l'inflammation du SNC. NLRX1 est un récepteur 
immunitaire inné de type NOD qui inhibe les principales voies inflammatoires. Ce récepteur est 
localisé dans les mitochondries. Plusieurs études ont démontré que NLRX1 inhibe la mort 
cellulaire, augmente la production d’ATP et atténue le stress oxydatif. Dans ce projet de recherche, 
nous démontrons que NLRX1 potentialise l'absorption de glutamate astrocytaire en renforçant les 
fonctions mitochondriales et l'activité fonctionnelle des transporteurs de glutamate, en utilisant des 
cultures d'astrocytes primaires provenant de souris WT et Nlrx1-/-. De plus, nous démontrons que 
NLRX1 inhibe la libération de glutamate par les astrocytes en réprimant l’exocytose de glutamate 
médiée par le Ca2+. Notre étude identifie pour la première fois NLRX1 comme un régulateur 
potentiel de l'homéostasie du glutamate dans le SNC. 
 
Mots-clés: NLRX1; astrocytes; SNC; absorption de glutamate; libération de glutamate; 
excitotoxicité. 
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Abstract: Uptake of glutamate from the extracellular space and glutamate release to neurons are 
two major processes conducted by astrocytes in the central nervous system (CNS) that protect 
against glutamate excitotoxicity and strengthen neuronal firing, respectively. During 
inflammatory conditions in the CNS, astrocytes may lose one or both of these functions, resulting 
in accumulation of the extracellular glutamate, which eventually leads to excitotoxic neuronal 
death, which in turn worsens the CNS inflammation. NLRX1 is an innate immune NOD-like 
receptor that inhibits the major inflammatory pathways. It is localized in the mitochondria and 
was shown to inhibit cell death, enhance ATP production, and dampen oxidative stress. In the 
current work, using primary murine astrocyte cultures from WT and Nlrx1-/- mice, we 
demonstrate that NLRX1 potentiates astrocytic glutamate uptake by enhancing mitochondrial 
functions and the functional activity of glutamate transporters. Also, we report that NLRX1 
inhibits glutamate release from astrocytes by repressing Ca2+-mediated glutamate exocytosis. Our 
study, for the first time, identified NLRX1 as a potential regulator of glutamate homeostasis in 
the CNS. 
Keywords: NLRX1; astrocytes; CNS; glutamate uptake; glutamate release; excitotoxicity 
 
1. Introduction 
Astrocytes are the most numerous glial cell type in the central nervous system (CNS). They 
perform many pivotal functions associated with neuronal support and maintenance of the CNS 
homeostasis [1]. One of these crucial functions is to uptake excess synaptically-released glutamate 
(the major excitatory neurotransmitter in the CNS) [2,3] from the extracellular space, metabolize 
it, and send it back to neurons [4,5]. This glutamate uptake is mediated primarily by the excitatory 
amino acid transporters 1 and 2 (EAAT1 and EAAT2), expressed by astrocytes (known in mice as 
glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1), respectively) [6–
11]. In astrocytes, under physiological conditions, the uptake of glutamate against its concentration 
gradient relies on glutamate transporters and Na+/K+ ATPase that consumes high levels of 
intracellular adenosine triphosphate (ATP) [12,13]. Many factors in the CNS influence the 
expression, trafficking, and functional activity of glutamate transporters in astrocytes, including 
hormones, growth factors, inflammatory mediators, and oxidative stress [14–16]. 
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Recent studies suggested that, along with glutamate uptake, astrocytes release glutamate, 
which helps synchronize and intensify firing of the surrounding neurons [4,17,18]. Astrocytic 
glutamate release is mediated mostly by Ca2+-dependent exocytosis [19]. In astrocytes, part of the 
sequestrated glutamate is transferred into small intracellular vesicles [20,21] by activation of the 
vesicular glutamate transporters 1 and 2 (VGLUT1 and VGLUT2), derived by the proton gradient 
generated by the vacuolar (H+) ATPase (V-ATPase) [22–24]. Astrocytes also express a Ca2+ sensor 
(synaptotagmin 4, 7, or 11) [25–27] and vesicular fusion proteins (vesicle-associated membrane 
protein 2 and 3 (VAMP2 and VAMP3)) [20,28]. In response to intracellular Ca2+ elevation, caused 
by Ca2+ release from the endoplasmic reticulum (ER), vesicular fusion proteins (VAMP2 and 
VAMP3) fuse with the astrocyte cell membrane fusion proteins (syntaxin and soluble N-
ethylmaleimide-sensitive factor attachment protein 23 (SNAP23)) [29–31], resulting in glutamate 
release from the vesicles into the extracellular space. 
In the context of CNS pathologies, astrocytes respond to inflammation by losing some of their 
vital functions or acquiring some deleterious effects that aggravate inflammatory conditions in the 
CNS and delay the processes of recovery [1]. Previous studies showed that neuropathological 
conditions in the CNS, such as brain trauma, infection by human immunodeficiency virus (HIV), 
multiples sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and 
Parkinson’s disease (PD) are associated with accumulation of glutamate in the extracellular space, 
caused by reduced glutamate uptake and/or increased glutamate release by astrocytes [32–37]. 
Excess extracellular glutamate induces hyperstimulation of glutamate receptors in neurons and 
eventually leads to neuronal death, in a process known as “glutamate excitotoxicity” [38]. The 
excess of extracellular glutamate and subsequent neuronal death, in turn, enhance the 
inflammatory response and worsen the pathological conditions in the CNS [38]. 
NOD-like receptors (NLRs) are cytosolic innate immune molecules that can exert either 
positive or negative effects on inflammation in the CNS [39]. NLRX1 is a recently discovered 
anti-inflammatory NLR that inhibits nuclear factor-κB (NF-κB) and RIG-1-MAVs signaling 
pathways, thus inhibiting antimicrobial immune responses [40–44] and sterile inflammations [45]. 
Since the introduction of Nlrx1-/- mice, many studies implicated NLRX1 in the development of 
various pathologies. For example, Nlrx1-/- mice show excessive inflammatory response following 
Influenza virus infection and LPS treatment [41]. Also, Nlrx1-/- mice show exacerbated severity of 
inflammatory bowel disease (IBD) [46] and increased incidence of colitis-associated colonic 
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cancer [45]. In the CNS, lack of Nlrx1 in mice is associated with an excessive inflammation 
following CNS trauma [47], earlier onset, and a more aggressive course of the experimental 
autoimmune encephalomyelitis (EAE), a mouse model of MS [48]. Moreover, using a 
neuroblastoma cell line, NLRX1 was shown to inhibit neuronal death and redirect rotenone-treated 
neurons towards apoptosis instead of necrosis [49]. Unlike other NLRs, NLRX1 is located at the 
mitochondria. It enhances various mitochondrial functions and activities such as ATP production 
and respiration while inhibiting oxidative stress and apoptosis [44,49–54]. 
In the current study, we investigated the role of NLRX1 in glutamate uptake and release by 
primary murine astrocytes, and the potential mechanisms by which NLRX1 mediates its effects. 
2. Materials and Methods 
2.1. Mice 
All mice handling and manipulations were approved by the Institutional Animal Care and Use 
Committee at the University of Sherbrooke (Protocols #280-15, 4 April 2017) according to the 
Canadian Council on Animal Care. All mice were bred on C57/BL6J background. Wild-type (WT) 
mice were bred in-house in the same conditions as Nlrx1-/- mice that were kindly provided by Dr. 
Jenny P. Y. Ting (Chapel Hill, NC, USA).  
2.2. Primary Mouse Astrocyte Cultures 
Glial cultures were prepared from 1-day-old pups, as previously described [55]. Pups were 
sacrificed by decapitation, and brains were harvested and placed in 100 mm culture plates. Brain 
tissue was dissociated by a commercial razor blade, followed by triturating in 10 mL DMEM/F12 
medium (Wisent Inc., Montreal, QC, Canada) containing 10% deactivated fetal bovine serum 
(dFBS), 2 mM L-glutamine, 1% MEM amino acid, 1% sodium pyruvate, and 1% penicillin-
streptomycin and amphotericin B (all from Wisent Inc., Montreal, QC, Canada). Dissociated tissue 
was passed through 70 µm cell strainer to remove tissue debris. Cells were plated in 100 mm cell 
culture plates (Corning Inc., Brooklyn, NY, USA) with DMEM/F12 complete medium and 
incubated in 37 °C incubator with 5% CO2. The medium was changed every 2–3 days to wash out 
cells other than glial cells. After 21 days, glial cultures were resuspended in 10% dimethyl 
sulfoxide (DMSO) in dFBS (freezing medium) and were frozen at −80 °C. One week before the 
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experiments, cells were thawed and reseeded in 100 mm culture plates, in complete DMEM/F12 
medium. Cells were stained with CD11b (eBioscience/Thermofisher scientific, Waltham, 
Massachusetts, USA # 12-0112-81) as a marker for microglia and the percentage of CD11b-
expressing cells was measured by flow cytometry. In our experiments, we used cultures containing 
less than 10% CD11b+ cells (astrocytes ≥90%) since additional purification of astrocytes did not 
affect the glutamate uptake or release. 
2.3. Glutamate Uptake and Release Assay 
The assay was modified from Piao et al. 2015 [56]. 100,000 astrocytes were seeded in each 
well of a 96-well plate, and washed 2 times with Hank’s Balanced Salt Solution (HBSS) containing 
Ca2+ (Wisent Inc., Montreal, QC, Canada): 1.26 mM CaCl2 (anhydrous), 5.36 mM KCl, 0.44 mM 
KH2PO4, 0.811 mM MgSO4 (anhydrous), 137 mM NaCl, 0.336 mM Na2HPO4 (anhydrous), 4.166 
mM NaHCO3, and 5.55 mM D-glucose, pH 7.25 ± 0.15 or Ca2+-free Lock’s solution: 140 mM 
NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 MgSO4, 11 mM glucose, and 15 mM HEPES-NaOH. 
For glutamate uptake, cells were incubated with 100 or 200 µM glutamate in the Ca2+-containing 
HBSS for 4 h, while for glutamate release, astrocytes were incubated in Ca2+-containing HBSS or 
Ca2+-free Lock’s solution for 1 h, in the 37 °C with 5% CO2 incubator. Then, culture supernatant 
was collected, and glutamate concentration in the medium was measured using a glutamate 
colorimetric assay kit (Sigma-Aldrich, Oakville, ON, Canada # MAK004 or Abcam, Toronto, ON, 
Canada #ab83389) according to the manufacturer’s instructions. Glutamate uptake by astrocytes 
was measured by subtracting the amount of glutamate measured in the medium from the amount 
initially added to the cells. Both glutamate uptake and release by astrocytes were normalized to 
the amount of protein in the corresponding cells, measured by Bradford assay (Bio-Rad, Montreal, 
QC, Canada). 
2.4. Quantitative Real-Time PCR (qPCR) 
RNA was extracted from astrocytes using TRIzol reagent (Life Technologies 
Inc./Thermofisher Scientific, Waltham, Massachusetts, USA # 15596-018) according to the 
manufacturer’s instructions. cDNA was synthesized from RNA, using Oligo(dT) primer (IDT, 
Coralville, Iowa, USA), dNTP Mix, M-MuLV Reverse Transcriptase, M-MuLV Reverse 
Transcriptase Buffer, and RNase inhibitor (all from New England Biolabs, Whitby, ON, Canada), 
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as previously described [55]. qPCR was performed using KiCqStart® SYBR® Green qPCR 
ReadyMix (Sigma-Aldrich, Oakville, ON, Canada # KCQS00). The ΔΔCT method was used to 
calculate the relative gene expression to 18S as a housekeeping gene [57]. Primer sequences used 
(IDT, Coralville, Iowa, USA) are shown in Table 1.  
Table 1. Primer sequences used for qPCR. 
18S F: 5′ CGG CTA CCA CAT CCA AGG AA ′3 
R: 5′ GCT GGA ATT ACC GCG GCT ′3 
Exocytosis 
V-ATPase d2 F: 5′ TTC AGT TGC TAT CCA GGA CTC GGA ′3 
R: 5′ GCA TGT CAT GTA GGT GAG AAA TGT GCT CA ′3 
VGLUT1 F: 5′ GGT GGA GGG GGT CAC ATA C ′3 
R: 5′ AGA TCC CGA AGC TGC CAT AGA ′3 
VGLUT2 F: 5′ CCC TGG AGG TGC CTG AGA A ′3 
R: 5′ GCG GTG GAT AGT GCT GTT GTT ′3 
Synaptotagmin 11 F: 5′ GAC ACT TGC CGA AGA TGG ATA TC ′3 
R: 5′ TGC GTT TTC TGC CGT AGT AGA ′3 
VAMP2 F: 5′ CAC AAT CTG GTT CTT TGA GGA G ′3 
R: 5′ AGA GAC TTC AGG CAG GAA TTA G ′3 
VAMP3 F: 5′ CTC ACC AAG GCA TCA GTC TG ′3 
R: 5′ ATT CTA AGA GCA CCA GGC ATC ′3 
Syntaxin 1a F: 5′ TCC AAG CTA AAG AGC ATT GAG C ′3 
R: 5′ GGC GTT GTA CTC GGA CAT GA ′3 
SNAP23 F: 5′ AAT CCT GGG TTT AGC CAT TGA GTC ′3 
R: 5′ TTG GTC CAT GCC TTC TTC TAT GC ′3 
Glutamate transporters 
GLT-1 F: 5′ CGA TGA GCC AAA GCA CCG AA ′3 
R: 5′ CTG GAG ATG ATA AGA GGG AGG ATG ′3 
GLAST F: 5′ TCA AGT TCT GCC ACC CTA CC ′3 
R: 5′ TCT GTC CAA AGT TCA GGT CAA ′3 
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2.5. Flow Cytometry Staining 
To measure the total protein expression of glutamate transporters, intracellular staining was 
performed (protocol modified from Gharagozloo et al. 2018 and Schwarz et al. 2013) [58,59]. WT 
and Nlrx1-/- astrocytes were washed with phosphate-buffered saline (PBS), fixed, permeabilized, 
and blocked with 5% dFBS in washing buffer. Cells were stained with the anti-GLT-1 antibody 
(Novus Biologicals, Centennial, CO, USA # NBP1-20136) diluted 1:100 or anti-GLAST antibody 
(Novus Biologicals, Centennial, CO, USA # NB100-1869) diluted 1:200 and incubated for 30–40 
min. Astrocytes were washed twice and incubated with the secondary anti-rabbit IgG antibody, 
Alexa Fluor® 555 Conjugated (New England Biolabs, Whitby, ON, Canada #4413) diluted 1:1000, 
for 20 min. Cells were washed twice after the secondary antibody and resuspended in PBS. 
To measure the cell surface expression of the transporters, astrocytes were washed and stained 
using the same previous procedure, but with no cell fixation or permeabilization. 
To detect the activity of reactive oxygen species (ROS), dihydrorhodamine 123 (DHR) was 
added to the cells to a final concentration of 0.5 µg/mL and incubated for 15 min at 37 °C, then 
cells were resuspended in PBS (protocol modified from Gris et al. 2008 and Farrell et al. 2011) 
[60,61]. 
Sample acquisition was realized using Beckman Coulter CytoFlex (Beckman Coulter, Brea, 
CA, USA). Data analysis was performed, and histograms produced using CytExpert 2.3 software 
(Beckman Coulter, Brea, CA, USA). 
2.6. Measurement of Intracellular ATP 
The assay was performed using the ATP bioluminescent assay kit (Sigma-Aldrich, Oakville, 
ON, Canada # FLAA) according to the manufacturer’s instructions, modified from Marcaida et al. 
1997 [62]. 100,000 astrocytes from WT and Nlrx1-/- mice were lysed with 400 µl of somatic cell 
ATP-releasing reagent (Sigma-Aldrich, Oakville, ON, Canada # FLSAR). In a white opaque 96-
well plate, 100 µl of the ATP reaction mix was added to each well and incubated for 3 min. 
Samples (100 µl) from the ATP standard or the cell lysate were added to the reaction mix and 
vigorously mixed. Immediately, using a luminometer, the amount of light produced from the 
reaction was measured, which reflected the amount of ATP in each well. 
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2.7. Measurement of Mitochondrial DNA (mtDNA) 
DNA was extracted from astrocytes using TRIzol reagent (Life Technologies 
Inc./Thermofisher Scientific, Waltham, Massachusetts, USA # 15596-018) according to the 
manufacturer’s instructions. qPCR was performed, as previously described, to compare the relative 
amount of mtDNA between WT and Nlrx1-/- astrocytes [63], using 100 ng of the extracted DNA 
and KiCqStart® SYBR® Green qPCR ReadyMix (Sigma-Aldrich, Oakville, ON, Canada # 
KCQS00). To estimate the amount of mtDNA, the mitochondrial DNA region (D-loop) was 
amplified, using the two primer sequences: D1 (5′-CCC AAG CAT ATA AGC TAG TAC-3′) and 
D2 (5′-ATA TAA GTC ATA TTT TGG GAA CTA C-3′), with the thermal cycling protocol 95 
°C for 20 s, 55 °C for 20 s, 72 °C for 80 s for 30 cycles after an initial denaturation. To estimate 
the amount of nuclear DNA as a reference, the (apo-B) region was amplified, using the two primer 
sequences: 5′-CGT GGG CTC CAG CAT TCT A-3′ and 5′-TCA CCA GTC ATT TCT GCC TTT 
G-3′, with the two-step thermal cycling protocol 95 °C for 10 s and 60 °C for 30 s for 40 cycles 
after an initial denaturation at 95 °C for 1 min. The relative amount of mtDNA to the nuclear DNA 
was calculated by the ΔΔCT method. 
2.8. Statistical Analysis 
All statistical analysis was conducted using GraphPad Prism 8 software (GraphPad, San 
Diego, CA, USA). Results were expressed as the mean ± standard error of the mean (SEM). 
Statistical differences between WT and Nlrx1-/- astrocytes were assessed by Mann–Whitney test. 
Glutamate uptake and glutamate release using different treatments were assessed by two-way 
ANOVA followed by Tukey’s test. The significance level was set at p < 0.05. 
3. Results 
3.1. NLRX1 Inhibits Excess Glutamate Release and Enhances Glutamate Uptake by Astrocytes 
To determine the role of NLRX1 in the glutamate release and uptake by astrocytes, we 
incubated primary astrocyte cultures from WT and Nlrx1-/- mice with or without glutamate in a 
Ca2+-containing medium. Our data shows that in the cultures incubated with the glutamate-free 
medium for 4 h (Figure 1A) or 1 h (Figure 2A), Nlrx1-/- astrocytes released significantly higher 
levels of glutamate compared to WT astrocytes. In the cultures incubated with 100 µM glutamate, 
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there was no significant difference in the glutamate uptake between WT and Nlrx1-/- astrocytes 
(Figure 1B). However, when we challenged both cultures with a higher concentration of glutamate 
(200 µM), WT astrocytes significantly enhanced their glutamate uptake, while there was no 
significant change in the Nlrx1-/- astrocytes’ glutamate uptake (Figure 1B). Therefore, after 
incubation with 200 µM glutamate, WT astrocytes had a significantly higher glutamate uptake 
(fivefold) than Nlrx1-/- astrocytes (Figure 1B). 
 
Figure 1. NLRX1 inhibits glutamate release and enhances glutamate uptake by astrocytes. 
(A) WT and Nlrx1-/- astrocyte cultures were incubated in glutamate-free, Ca2+-containing HBSS 
medium. After 4 hrs, the culture supernatant was collected, and glutamate release in the medium 
was measured (n = 7), ** p < 0.01 as determined by Mann–Whitney test. (B) For evaluation of 
glutamate uptake, astrocyte cultures were incubated with 100 or 200 µM glutamate in the Ca2+-
containing HBSS medium (n = 5), * p < 0.05 as determined by Tukey’s test, results are presented 
as mean ± SEM. 
3.2. Nlrx1-/- Astrocytes’ Excess Glutamate Release Is Ca2+-Dependent 
Given that glutamate release by astrocytes is mediated primarily by the elevation of 
intracellular Ca2+ levels [18], first, we examined whether the presence of extracellular Ca2+ plays 
a role in glutamate release from Nlrx1-/- astrocytes. We incubated WT and Nlrx1-/- astrocyte 
cultures in a Ca2+-containing or Ca2+-free medium for 1 h, followed by the measurement of 
glutamate in the medium. We observed that removal of Ca2+ from the medium resulted in a 
significant increase in glutamate release from WT astrocytes, while no significant changes in 
glutamate release were observed in the Nlrx1-/- astrocytes (Figure 2A). This suggests that the 
presence of extracellular Ca2+ does not have a significant effect on glutamate release in Nlrx1-/- 
cultures. 
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We further assessed whether this glutamate release is mediated by Ca2+ release from the 
intracellular Ca2+ stores, including ER and mitochondria. We incubated WT and Nlrx1-/- astrocyte 
cultures with different concentrations of 2-Aminoethyl diphenylborinate (2-APB, an inhibitor of 
inositol-1,4,5-trisphosphate (IP3) receptors that inhibits Ca2+ release from the ER) [64] or 
Cyclosporin A (CsA, an inhibitor of mitochondrial Ca2+ release) [65] in the Ca2+-free medium. A 
significant reduction was detected in the glutamate release from 2-APB-treated Nlrx1-/- astrocytes 
at both concentrations, compared to WT (Figure 2B). By contrast, in cultures treated with CsA, no 
significant change was detected in both genotypes (Figure 2C). 
 
Figure 2. Excess Ca2+ release from the ER mediates glutamate release from Nlrx1-/- 
astrocytes. (A) WT and Nlrx1-/- astrocytes were incubated in a Ca2+-containing HBSS buffer or 
Ca2+-free Lock’s solution for 1 h (n = 7); (B) astrocyte cultures were incubated with 0.01 or 0.05 
µM of 2-APB (n = 5), or (C) with 2 or 10 µM of CsA (n = 6) in the Ca2+-free Lock’s solution for 
1 h. The supernatant was collected from all cultures and glutamate in the medium was measured 
by the glutamate assay kit. * p < 0.05 as determined by Tukey’s test, results are presented as mean 
± SEM. 
3.3. Glutamate Release by Nlrx1-/- Astrocytes Is Mediated By Exocytosis 
Since we found that the NLRX1-mediated glutamate release is Ca2+-dependent, we further 
evaluated whether it is mediated by exocytosis. We measured gene expression of the proteins 
involved in exocytosis, upstream and downstream of the Ca2+ release from the ER, in WT and 
Nlrx1-/- astrocyte cultures. The results demonstrated that the mRNA expression of the astrocytic 
Ca2+ sensor, synaptotagmin 11, and the vesicular fusion proteins (VAMP2 and VAMP3) was 
significantly upregulated in Nlrx1-/- astrocytes relative to WT (Figure 3A), while no significant 
change was observed in the mRNA expression of the cell membrane fusion proteins (Syntaxin 1a 
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and SNAP23) (Figure 3B) or the proteins upstream of the Ca2+ release (V-ATPase d2, VGLUT1, 
and VGLUT2) (Figure 3C). 
 
 
 
Figure 3. Increased mRNA expression of the proteins of exocytosis in Nlrx1-/- astrocytes. 
mRNA expression of the proteins of exocytosis in WT and Nlrx1-/- astrocytes shows (A) 
significant upregulation of mRNA expression of the Ca2+ sensor, synaptotagmin 11, and vesicular 
fusion proteins, VAMP2 and VAMP3, in Nlrx1-/- astrocytes compared to WT; (B) no significant 
change in the cell membrane fusion proteins’ mRNA expression; and (C) no significant change 
in the expression of the proteins upstream of Ca2+ release from the ER. ** p < 0.01 and * p < 0.05 
as determined by Mann–Whitney test (n ≥ 5), results are presented as mean ± SEM. 
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3.4. mRNA and Protein Expression of Glutamate Transporters in Astrocytes 
To further investigate the mechanism by which NLRX1 enhances glutamate uptake, we 
measured the relative gene expression of the astrocytes’ glutamate transporters, GLT-1 and 
GLAST, in WT and Nlrx1-/- astrocyte cultures, using qPCR. The mRNA expression of both 
transporters was significantly higher in Nlrx1-/- astrocyte cultures relative to WT (Figure 4A). In 
parallel, we stained WT and Nlrx1-/- astrocytes with anti-GLT-1 or anti-GLAST antibodies and 
quantified the total protein expression and the cell surface expression of both transporters by flow 
cytometry. As shown in Figure 4B and 4C, no significant change was detected in either GLT-1 or 
GLAST total protein expression (Figure 4B) or cell surface expression (Figure 4C) between 
astrocytes of both genotypes. 
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Figure 4. mRNA and protein expression of GLT-1 and GLAST in astrocytes. (A) mRNA 
expression of GLT-1 and GLAST is significantly upregulated in Nlrx1-/- astrocytes compared to 
WT (n = 5). ** p < 0.01 as determined by Mann–Whitney test; (B) the total protein expression of 
GLT-1 and GLAST proteins in WT and Nlrx1-/- astrocytes was measured by flow cytometry (n = 
5); (C) the cell surface expression of both transporters on astrocytes was measured by flow 
cytometry (n = 7). Representative flow cytometric histograms presented on the left side, p > 0.05 
as determined by Mann–Whitney test, results are presented as mean ± SEM. 
3.5. NLRX1 Enhances Mitochondrial Functions in Astrocytes 
The optimal function of glutamate transporters requires an enormous amount of energy 
[12,13]. Accordingly, we measured levels of intracellular ATP in both WT and Nlrx1-/- astrocytes. 
We found that Nlrx1-/- astrocytes have significantly less (20%) intracellular ATP compared to WT 
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(Figure 5A). Since oxidative stress exerts a negative effect on the functional activity of the 
transporters [66,67], we measured ROS activity in both WT and Nlrx1-/- astrocytes by flow 
cytometry. Our results demonstrated that Nlrx1-/- astrocytes have significantly higher oxidative 
activity than WT (Figure 5B). Since mitochondria are the major source of intracellular ATP and 
ROS in the cells, we evaluated the number of mitochondria in WT and Nlrx1-/- astrocytes. No 
significant difference was detected in the amount of mtDNA between WT and Nlrx1-/- astrocytes 
(Figure 5C). 
 
Figure 5. NLRX1 enhances mitochondrial functions in astrocytes. (A) The level of 
intracellular ATP was measured in WT and Nlrx1-/- astrocytes using an ATP bioluminescent assay 
kit (n = 5); (B) the level of oxidative activity was measured in WT and Nlrx1-/- astrocytes by flow 
cytometry (n = 4); (C) the difference between the amount of mtDNA in WT and Nlrx1-/- astrocytes 
was measured by qPCR (n = 3). * p < 0.05 as determined by Mann–Whitney test, results are 
presented as mean ± SEM. 
4. Discussion 
In this study, we report that the anti-inflammatory [40–45,47,48] and prosurvival molecule 
[49], NLRX1, helps maintain glutamate homeostasis in the CNS. Our findings suggest that 
NLRX1 enhances astroglial glutamate uptake by promoting the functional activity of glutamate 
transporters and inhibits glutamate release from astrocytes by suppressing Ca2+-mediated 
glutamate exocytosis. To our knowledge, this is the first time that one protein has been shown to 
be implicated in both processes that regulate glutamate homeostasis. 
Given that GLT-1 and GLAST are responsible for the uptake of more than 90% of the 
extracellular glutamate in the CNS [68,69], we measured the mRNA and protein expression of 
these glutamate transporters in astrocytes from WT and Nlrx1-/- mice. Unexpectedly, the mRNA 
expression of both transporters was significantly higher in Nlrx1-/- astrocytes than WT. However, 
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when we measured the total protein expression, as well as the cell surface expression of both 
transporters, we did not see any significant difference between astrocytes of both genotypes. These 
findings suggest that the enhanced glutamate uptake in WT astrocytes cannot be attributed to 
changes in the transcription or translation of the glutamate transporters. In line with our findings, 
Conrad and Stoffel reported that the direct phosphorylation of GLAST protein by protein kinase 
C (PKC) reduces its glutamate uptake activity, while immunofluorescence does not show any 
effect on its protein expression [70]. Another study revealed that arachidonic acid (AA) 
downregulates glutamate uptake by EAAT-1 by decreasing its affinity to glutamate and the 
maximal transport rate approximately 30% with no effect on the expression of its protein [71]. In 
a third study, Trotti et al. reported that oxidative stress by H2O2 induces direct oxidation of the 
sulfhydryl (SH) group of both transporters, which decreases their glutamate uptake with no protein 
degradation or reduction in their surface expression [72]. 
Since NLRX1 is localized in the mitochondria, we hypothesized that NLRX1 enhances the 
glutamate uptake activity of both GLT-1 and GLAST by improving mitochondrial functions in 
astrocytes. The level of intracellular ATP in astrocytes is one of the crucial factors that determine 
the functional activity of glutamate transporters [12,13]. Many previous studies reported that ATP 
depletion, as in cases of brain ischemia, induces glutamate uptake failure caused by loss or reversal 
of the transporters’ function [73,74]. To pay for its own energy consumption, a large portion of 
glutamate metabolites in astrocytes is consumed in the tricarboxylic acid (TCA) cycle to produce 
more ATP [75]. Interestingly, we found that Nlrx1-/- astrocytes contain 20% less ATP that WT 
astrocytes, which could either be a cause and/or a result of the reduced glutamate uptake by these 
cells. Nevertheless, these data, in agreement with the previous studies [50,51], suggest that NLRX1 
enhances mitochondrial ATP production. 
Moreover, it was reported that the intracellular oxidative stress induced by H2O2 reduces the 
functional activity of glutamate transporters [66,67]. In this regard, we measured the level of ROS 
activity in both WT and Nlrx1-/- astrocytes. Our results demonstrated that Nlrx1-/- astrocytes have 
50% more oxidative activity than WT, which could be responsible for the significant deficiency 
of their glutamate uptake. Furthermore, since there was no difference in the level of mtDNA 
between WT and Nlrx1-/- astrocytes, we excluded the possibility that NLRX1 increases the number 
of mitochondria. 
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Taken together, our results suggest that NLRX1 enhances mitochondrial functions in 
astrocytes, and thus boosts the functional activity of both GLT-1 and GLAST, rather than their 
protein expression. This effect of NLRX1 on the transporters is achieved by suppressing oxidative 
stress and, partially, by maintaining sufficient ATP production. 
Recent studies suggest that astrocytes express components necessary for the Ca2+-mediated 
exocytosis, which is the principal mechanism of astroglial glutamate release under physiological 
conditions [4,17–19]. We evaluated whether the excess glutamate release from Nlrx1-/- astrocytes 
is Ca2+-dependent. First, to exclude the role of extracellular Ca2+, we incubated astrocytes in a 
Ca2+-free instead of the Ca2+-containing medium. We observed that WT astrocytes significantly 
upregulated their glutamate release after Ca2+ removal, which agrees with the previously published 
report by Kostic et al. (2017) [76]. The removal of Ca2+ from the medium stimulates Ca2+ release 
from the intracellular Ca2+ stores and results in augmentation of glutamate release from astrocytes 
[76]. However, this does not explain the phenotype in Nlrx1-/- astrocytes, as there was no change 
between their glutamate release in the Ca2+-containing and the Ca2+-free media, probably because 
they had already reached their maximum capacity of glutamate release, and Ca2+ removal does not 
result in any additional effect. In the second step, we evaluated whether this glutamate release 
occurs in response to Ca2+ release from the intracellular Ca2+ stores. We found that inhibiting Ca2+ 
release from the mitochondria does not exhibit any significant effect while inhibiting Ca2+ release 
from the ER reduces the excess glutamate release from Nlrx1-/- astrocytes. These observations 
corroborate previous findings that ER Ca2+ plays an essential role in glutamate release [4,17]. 
Consequently, Nlrx1-/- astrocytes show higher mRNA expression of exocytosis proteins 
downstream of Ca2+ release from the ER, including the Ca2+ sensor, synaptotagmin 11, and the 
vesicular fusion proteins (VAMP2 and VAMP3). In contrast, there is no significant change in the 
expression of the cell membrane fusion proteins (Syntaxin 1 a and SNAP23), or the proteins 
preceding Ca2+ release from the ER (V-ATPase d2, VGLUT1, and VGLUT2). Therefore, our 
results suggest that the excess glutamate release from Nlrx1-/- astrocytes is mediated by excess Ca2+ 
release from the ER, followed by an augmentation in the expression of the molecules of exocytosis 
as a result of the excess Ca2+ release. Collectively, these data provide evidence that NLRX1 
mediates its inhibitory effect on glutamate release from astrocytes mainly by suppressing Ca2+ 
release from the ER, which consequently suppresses glutamate exocytosis. 
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The connection between the two mechanisms by which NLRX1 mediates its effects on 
astroglial glutamate uptake and release is still unclear. Being situated in the mitochondria, it is 
plausible that NLRX1 modifies mitochondrial functions [44,49–51]. However, the mechanism by 
which NLRX1 modifies the function of the ER requires more in-depth investigations. 
In conclusion, in the current study, we provide evidence that NLRX1 enhances astroglial 
glutamate uptake and inhibits excess glutamate release from astrocytes, thus maintaining 
glutamate homeostasis in the CNS (Figure 6 - modified from the graphical abstract of our recent 
publication) [4]. Consequently, NLRX1 represents a potential therapeutic target for the 
inflammatory and neurodegenerative diseases associated with glutamate excitotoxicity in the CNS. 
Figure 6. NLRX1 maintains glutamate homeostasis in the CNS. (A) Uptake of the 
extracellular glutamate by astrocytes is mediated by the glutamate uptake transporters (GLT-1 
and GLAST); (B) Ca2+-mediated exocytosis mediates glutamate release from astrocytes, in 
response to Ca2+ release from the ER. The released glutamate helps to synchronize and reinforce 
the firing of the surrounding neurons; (C) NLRX1 enhances astroglial glutamate uptake and 
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inhibits its Ca2+-mediated glutamate exocytosis, hence maintaining glutamate homeostasis in the 
CNS. 
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GLAST Glutamate–aspartate transporter 
GLT-1 Glutamate transporter-1 
ATP Adenosine triphosphate 
VGLUT1 and VGLUT2 Vesicular glutamate transporters 1 and 2 
V-ATPase Vacuolar (H+) ATPase  
VAMP2 and VAMP3 Vesicle-associated membrane protein 2 and 3 
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NLRX1 NOD-like receptor X1 
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IBD Inflammatory bowel disease 
EAE Experimental autoimmune encephalomyelitis 
WT Wild-type 
Nlrx1-/- Nlrx1 knockout 
dFBS Deactivated fetal bovine serum 
DMSO Dimethyl sulfoxide 
HBSS Hank’s Balanced Salt Solution 
qPCR Quantitative real-time PCR 
PBS Phosphate-buffered saline 
ROS Reactive oxygen species 
DHR Dihydrorhodamine 123 
mtDNA Mitochondrial DNA 
SEM Standard error of the mean 
2-APB 2-Aminoethyl diphenylborinate 
IP3 Inositol-1,4,5-trisphosphate 
CsA Cyclosporin A 
PKC Protein kinase C 
AA Arachidonic acid 
SH group Sulfhydryl group 
TCA Tricarboxylic acid 
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4. DISCUSSION 
Inflammatory conditions in the CNS are often complicated by glutamate excitotoxicity. During 
inflammation, reactive astrocytes may lose their function of glutamate uptake and/or release an 
excess amount of glutamate to the extracellular space. The resulting accumulating glutamate in the 
extracellular space is toxic to neurons, that eventually induces neuronal death. Neuronal death as 
a result of glutamate excitotoxicity reactivates the resident CNS cells and attracts more 
inflammatory cells to the CNS, which worsens inflammation and delays the recovery process 
(Dong et al. 2009; Wang and Qin 2010). Our molecule of interest, NLRX1, is an anti-inflammatory 
molecule in the CNS (Eitas et al. 2014; Theus et al. 2017) and a neuro-survival factor (Imbeault et 
al. 2014). Based on that, we investigated the role of NLRX1 in astroglial glutamate uptake and 
release, using primary murine astrocyte cultures from WT and Nlrx1-/- mice. Our results 
demonstrate, for the first time, that one protein, NLRX1, supports glutamate homeostasis mediated 
by astrocytes. We showed that NLRX1 enhances astroglial glutamate uptake and inhibits 
glutamate release from astrocytes. Therefore, we identify NLRX1 as a potential inhibitor of 
glutamate excitotoxicity in the CNS. 
4.1. Effect of NLRX1 on glutamate release by astrocytes 
Astroglial glutamate release is a recently discovered function of astrocytes in the CNS, which 
represents a part of the gliotransmitter release. The released glutamate from astrocytes modulates 
neurotransmitter release from the adjacent inhibitory or excitatory neurons and strengthens their 
firings. Yet, very little is known about the regulatory factors that stimulate or inhibit this astroglial 
function. By contrast, many studies identified various mechanisms mediating astroglial glutamate 
release. Among which, Ca2+-mediated exocytosis is the main proposed mechanism by which 
astrocytes release glutamate (Hamilton and Attwell 2010; Mahmoud et al. 2019; Malarkey and 
Parpura 2008; Parpura and Haydon 2000). In our experiments, when we incubated WT and Nlrx1-
/- astrocytes in a Ca2+-containing medium, Nlrx1-/- astrocytes released more than double the amount 
of glutamate released by WT astrocytes. As a first step, we assessed whether this excess glutamate 
release from Nlrx1-/- astrocytes is Ca2+-dependent. 
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4.1.1. Extracellular Ca2+ does not play a role in NLRX1-mediated astroglial glutamate release 
In work done by Hua and coworkers, using primary rat cortical astrocytes, they revealed that 
entrance of the extracellular Ca2+ to astrocytes may play a minor role in increasing the level of the 
[Ca2+]i and the subsequent glutamate release by astrocyte cultures. When they blocked Ca2+ entry 
by Cd2+, this resulted in a reduction of glutamate release from the astrocyte cultures (Hua et al. 
2004). Accordingly, to verify if extracellular Ca2+ plays a role in glutamate release in our case, we 
incubated WT and Nlrx1-/- astrocytes in a Ca2+-free medium. Unlike the results obtained by Hua 
et al., after Ca2+ removal, WT astrocytes upregulated their glutamate release to almost triple the 
amount of glutamate they released in the Ca2+-containing medium while no significant difference 
was seen in glutamate release by Nlrx1-/- astrocytes. Interestingly, the same observation of 
increased glutamate release by WT rat cortical astrocytes after Ca2+ removal was reported before 
by Kostic and colleagues. They explained this phenomenon by the fact that Ca2+ removal from the 
extracellular space stimulates Ca2+ release from the intracellular Ca2+ stores, hence enhancing 
glutamate release (Kostic et al. 2017). Nevertheless, these findings do not explain the phenotype 
of Nlrx1-/- astrocytes’ excess glutamate release, as there was no difference between their glutamate 
release in both media. This is probably because Nlrx1-/- astrocytes have already reached their 
maximum capacity of glutamate release and Ca2+ removal does not result in any additional effect. 
These findings suggest that glutamate release by Nlrx1-/- astrocytes is not mediated by Ca2+ entry 
from the culture medium. 
4.1.2. NLRX1 inhibits Ca2+ release from the ER in astrocytes 
Accumulating evidence suggests that glutamate release by astrocytes is mediated mostly by 
Ca2+ release from the ER in response to the GPCR stimulation followed by IP3 activation in 
astrocytes (Hamilton and Attwell 2010; Harada, Kamiya, and Tsuboi 2016; Hua et al. 2004; 
Mahmoud et al. 2019). In addition, using rat cortical astrocytes, Reyes and Parpura reported that 
mitochondrial Ca2+ also plays a role in modulating [Ca2+]i level, and thus modulates glutamate 
release by astrocytes. When they inhibited Ca2+ release from the mitochondria by CsA, they 
observed a significant reduction in glutamate release. Contrariwise, when they stimulated Ca2+ 
release from the mitochondria by FCCP, there was a remarkable increase in the astrocytic 
glutamate release (Reyes and Parpura 2008). 
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In our experiments, after excluding the role of the extracellular Ca2+, we investigated whether 
Ca2+ release from the intracellular Ca2+ stores, mitochondria and ER, mediates the excess 
glutamate release from Nlrx1-/- astrocytes. We incubated WT and Nlrx1-/- astrocytes with 2-APB 
(inhibitor of Ca2+ release from the ER) or CsA (inhibitor of Ca2+ release from the mitochondria). 
Treating astrocytes with 2-APB resulted in a significant reduction in glutamate release from Nlrx1-
/- astrocytes relative to WT, while no significant change was seen in glutamate release from CsA-
treated astrocytes between both genotypes. These data suggest that excess glutamate release from 
Nlrx1-/- astrocytes is mediated by excess Ca2+ release from the ER. These observations support the 
previous reports that ER is the main source of increased [Ca2+]i level in the mechanism of Ca2+-
mediated exocytosis in astrocytes (Hamilton and Attwell 2010; Harada et al. 2016; Hua et al. 2004; 
Mahmoud et al. 2019). 
4.1.3. NLRX1 inhibits glutamate exocytosis by astrocytes 
As we showed that excess glutamate release from Nlrx1-/- astrocytes is induced by excess Ca2+ 
release from the ER, finally, we evaluated whether it is mediated by exocytosis. We measured the 
mRNA expression of the proteins involved in exocytosis in WT and Nlrx1-/- astrocytes. Nlrx1-/- 
astrocytes showed significantly higher mRNA expression of the vesicular compartments of 
exocytosis downstream of Ca2+ release from the ER. These proteins include the astrocytic Ca2+ 
sensor, synaptotagmin 11, and the vesicular fusion proteins, VAMP2 and VAMP3. However, there 
was no significant difference in the mRNA expression of the cell membrane fusion proteins or 
proteins of exocytosis upstream of Ca2+ release from the ER. These observations suggest that 
exocytosis is significantly enhanced in Nlrx1-/- astrocytes relative to WT. 
Together these data suggest that NLRX1 inhibits glutamate release from astrocytes by 
suppressing Ca2+ release from the ER, and consequently suppressing Ca2+-mediated glutamate 
exocytosis.  
Two previous studies from the same group, using rat cortical astrocytes and brain tissue slices 
in addition to human astrocyte cultures from embryonic stem cells, demonstrated that 
inflammatory mediators, such as PGE2 and TNF-α, enhance Ca2+-mediated glutamate exocytosis 
by astrocytes in many CNS diseases (Bezzi et al. 1998, 2001). However, nothing is known about 
the regulatory factors of exocytosis under physiological conditions. To the best of our knowledge, 
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we report for the first time that NLRX1 regulates Ca2+-mediated glutamate exocytosis in healthy 
astrocytes. 
4.2. Effect of NLRX1 on glutamate uptake by astrocytes 
Glutamate uptake by astrocytes is one of the extensively studied functions of astrocytes in the 
CNS. The importance of this astrocytic function is highlighted by its implication in preventing 
glutamate excitotoxicity. Also, by converting glutamate to glutamine, astrocytes provide neurons 
with a precursor for active neurotransmitters’ synthesis. Till now, we know a lot about its 
mechanism, mediated by the glutamate transporters, EAAT1 and EAAT2 (Anderson and Swanson 
2000; Mahmoud et al. 2019). In addition, extensive studies focused on the regulation of astrocytic 
glutamate uptake. Various factors were reported to affect glutamate transporters’ expression, 
translation, post-translational modifications, and functional activity (Chi-Castañeda et al. 2017; 
Gegelashvili and Schousboe 1997; Mahmoud et al. 2019; Sattler and Rothstein 2006).  
In our study, we uncovered the role of NLRX1 on astroglial glutamate uptake. We incubated 
WT and Nlrx1-/- astrocytes with different concentrations of glutamate, and we measured how much 
astrocytes uptake from this extracellular glutamate. With the low concentration of glutamate, we 
did not see a significant difference in the glutamate uptake between both genotypes. However, 
when we increased glutamate concentration, WT astrocytes tripled the amount of glutamate they 
uptake/µg of protein. This observation agreed with the previous report published by Abe et al. 
They incubated rat cortical astrocytes with different concentrations of glutamate for different 
incubation periods. They reported that astrocytes increased their glutamate uptake capacity in a 
concentration and time-dependent manner (Abe, Abe, and Saito 2000). By contrast, Nlrx1-/- 
astrocytes did not show any significant difference in their glutamate uptake between both 
concentrations of glutamate. This created a fivefold increase in the glutamate uptake by WT 
astrocytes compared to Nlrx1-/- with the high concentration of glutamate.  
4.2.1. NLRX1 does not influence the protein expression of glutamate transporters 
Knowing that glutamate uptake by astrocytes is mediated by the glutamate transporters, GLT-
1 and GLAST (Eulenburg and Gomeza 2010; Lehre and Danbolt 1998), we measured their mRNA 
and protein expression in the astrocyte cultures of both genotypes. Surprisingly, the mRNA 
expression of both transporters was significantly higher in Nlrx1-/- astrocytes compared to WT, 
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which negatively correlates with our results of their glutamate uptake. By contrast, there was no 
significant difference in the total protein expression or the cell surface expression of both GLT-1 
and GLAST between both groups of astrocytes. 
Several possible explanations may interpret this lack of correspondence between the mRNA 
and protein expressions of glutamate transporters in Nlrx1-/- astrocytes (Greenbaum et al. 2003; 
Liu, Beyer, and Aebersold 2016). One possibility could be related to the various post-
transcriptional modifications occurring between the gene transcription and protein synthesis. 
These modifications include activation or inhibition of many signaling pathways, such as PKA, 
PKC, PI3K, and NF-κB (Chi-Castañeda et al. 2017; Gegelashvili and Schousboe 1997; Sattler and 
Rothstein 2006). Depending on the interactions with different environmental factors and other 
signaling pathways, activation of NF-κB could mediate either upregulation or downregulation of 
the protein expression of GLT-1 and GLAST (Chi-Castañeda et al. 2017; Gegelashvili and 
Schousboe 1997; Sattler and Rothstein 2006). Taking in consideration that NLRX1 is known to 
inhibit NF-κB pathway (Allen et al. 2011; Ma et al. 2019; Theus et al. 2017), it is possible that 
loss of the brakes on NF-κB activation reduces GLT-1 and GLAST protein expression relative to 
their mRNA expression in Nlrx1-/- astrocytes. The second possible cause might be the post-
translational modifications that reduce the protein half-life or induce its degradation, such as 
protein glycosylation, phosphorylation or oxidation (Greenbaum et al. 2003; Liu et al. 2016). 
Several reports demonstrated that protein oxidation by ROS results in protein damage and 
degradation (Davies, Lin, and Pacifici 1987; Pajares et al. 2015). This might be applicable in our 
case, as we showed later in our results that Nlrx1-/- astrocytes have more ROS activity than WT. 
In this regard, the effect of NF-κB activation and oxidative stress on the GLT-1 and GLAST 
proteins’ translation and post-translational modifications in Nlrx1-/- astrocytes remain to be 
determined. 
Nevertheless, these data suggest that NLRX1-mediated increased glutamate uptake cannot be 
attributed to transcriptional or translational modifications of glutamate transporters in astrocytes. 
In agreement with our findings, various factors were reported to influence glutamate uptake 
by astrocytes with no effect on the mRNA or protein expression of the transporters. Using Xenopus 
oocytes and human embryonic kidney cells (HEK293) expressing the cloned GLAST‐1 cDNA, 
Conrad and Stoffel reported that direct phosphorylation of GLAST protein by PKC reduced its 
glutamate uptake function. However, immunofluorescence staining did not show any difference 
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between the expression of the phosphorylated and the non-phosphorylated forms of the protein 
(Conradt and Stoffel 1997). H2O2 also inhibits the function of both transporters by direct oxidation 
of the sulfhydryl group (SH) of both transporter proteins in rat cortical astrocytes (Trotti et al. 
1997), without any effect on their mRNA or protein expression evidenced by qPCR, 
immunoblotting, and immunocytochemical techniques (Miralles et al. 2001). In another study, 
arachidonic acid was shown to reduce the functional activity of EAAT1 by decreasing its affinity 
to glutamate and its maximum glutamate transport rate, with no effect on its protein expression. 
The results in this study were obtained from HEK293 Cells and Xenopus oocytes transfected with 
EAAT1 – 3 (Zerangue et al. 1995).  
4.2.2. NLRX1 enhances mitochondrial functions and the functional activity of glutamate 
transporters in astrocytes 
The presence of a sufficient amount of intracellular ATP in astrocytes is mandatory to 
maintain normal functions of the glutamate transporters (Pellerin and Magistretti 1997; Sibson et 
al. 1998). Previous studies reported that brain ischemia is associated with reduced or depleted 
intracellular ATP, thus accompanied by glutamate uptake failure and even reversal of the 
transporters in severe cases (Grewer et al. 2008; Rossi et al. 2000). In addition, a significant part 
of the sequestrated glutamate in astrocytes is metabolized to α-ketoglutarate, which acts as a 
substrate for ATP production (McKenna 2013). Therefore, we were interested to know if NLRX1 
affects the level of intracellular ATP in astrocytes. We measured the level of intracellular ATP in 
WT and Nlrx1-/- astrocytes. As we expected, Nlrx1-/- astrocytes had 20% less intracellular ATP 
than WT, which could either be a cause or a result of the reduced glutamate uptake in these cells. 
Nonetheless, these data suggest that NLRX1 enhances intracellular ATP production in astrocytes.  
Furthermore, oxidative stress, specifically by H2O2, reduces the functional activity of the 
transporters in astrocytes (Sorg et al. 1997; Volterra et al. 1994) by direct oxidation of the SH 
group of both transporter proteins (Trotti et al. 1997). Therefore, we measured ROS activity in 
both WT and Nlrx1-/- astrocytes. Interestingly, we found that Nlrx1-/- astrocytes have about 50% 
more oxidative activity than WT, which may explain the significant reduction of their glutamate 
uptake activity.  
Similar to our obtained results from NLRX1, previous studies showed that many other factors 
regulate the function of the transporters indirectly by modulating the level of oxidative activity in 
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astrocytes. In a study on brain tissues from patients with AD, amyloid-β peptide induced oxidative 
stress in astrocytes and resulted in a reduction of glutamate uptake by astrocytes (González-Reyes 
et al. 2017). In another study, treating human astrocyte cultures from fetal brain tissue with IL-1β 
and IFN-ɣ pro-inflammatory cytokines induced ROS production by astrocytes and reduced their 
function of glutamate uptake (Sheng et al. 2013).  
Collectively, these results corroborate the data obtained from 2 independent research groups 
that NLRX1 enhances ATP production and inhibits oxidative stress in 2 different cell types, renal 
tubular epithelial cells (Stokman et al. 2017) and human breast cancer cells (Singh et al. 2019). 
Moreover, we measured mtDNA as an indication of the number of mitochondria, as previously 
described (Fuke et al. 2011). We did not find any significant difference in the amount of mtDNA 
between WT and Nlrx1-/- astrocytes. Therefore, we concluded that NLRX1 does not increase the 
number of mitochondria in astrocytes.  
When we incubated our cultures with 100 µM of glutamate, we did not see a significant 
difference in glutamate uptake between WT and Nlrx1-/- astrocytes, probably because the 
functional capacity of glutamate transporters in Nlrx1-/- astrocytes was enough to uptake such low 
concentration of glutamate. 
With 200 µM of glutamate, glutamate transporters need to increase their energy consumption 
and functional capacity to uptake such high concentration of glutamate, which was the case for 
WT astrocytes. However, probably because of the reduced intracellular ATP and increased ROS 
activity in Nlrx1-/- astrocytes, glutamate transporters could not increase their functional activity to 
uptake more glutamate and that is why we saw this significant difference between WT and Nlrx1-
/- astrocytes’ glutamate uptake only with the high concentration of glutamate. 
Taken all together, our findings suggest that NLRX1 enhances astroglial glutamate uptake by 
maintaining normal functional activity of the astrocytic glutamate transporters, GLT-1 and 
GLAST. This is achieved by damping intracellular oxidative stress and, at least partially by 
enhancing mitochondrial ATP production in astrocytes. 
4.3. How NLRX1 modulates the functions of the mitochondria and the ER 
The connection between these two mechanisms by which NLRX1 regulates astrocytic 
glutamate uptake and release is still unknown. Through its localization in the mitochondria, it is 
plausible that NLRX1 enhances mitochondrial functions. However, we report for the first time that 
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NLRX1 mediates an effect on the ER. Taking into consideration that the exact location of NLRX1 
in the mitochondria is still under debate, in which one research group reported that it is located in 
the outer mitochondrial membrane, based on immunofluorescence staining of HELA cells 
transfected with NLRX1-GFP  (Moore et al. 2008). Using similar imaging techniques, three other 
groups showed that it is situated in the mitochondrial matrix (Arnoult et al. 2009; Rhee et al. 2013; 
Singh et al. 2018). In vivo studies on Nlrx1-KD mice showed that NLRX1 also interacts with 
TRAF6 and IKK in the cytoplasm to inhibit NF-κB signaling pathway (Allen et al. 2011; Xia et 
al. 2011). It might be possible that NLRX1 is situated at the ER/mitochondrial transitions. 
The ER/mitochondrial transitions or contacts, also known as the mitochondria-associated 
membrane (MAM), are sites at which the outer mitochondrial membrane and the ER surface run 
in parallel at a constant distance ranging from 10 to 80 nm, as shown by the electron microscopy 
(Ilacqua et al. 2017). These contact sites were first isolated in 1990 (Vance 1990) and were 
visualized by fluorescence, later in 1998 (Rizzuto et al. 1998). Now, visualization of these contact 
sites is much improved thanks to the great microscopic technologies such as electron microscopy, 
electron tomography, and wide-field digital 3D deconvolution microscopy. Proteins expressed at 
both membranes of the MAM interact together to regulate many functions between both 
organelles. In case of ER stress, the chaperone glucose-regulated protein 75 (GRP75) and 
transglutaminase type 2 (TG2) induce Ca2+ transfer from the ER to the mitochondria, which 
stimulates the opening of mitochondrial transition pores to initiate apoptosis (D’eletto et al. 2018; 
Deniaud et al. 2008; Honrath et al. 2017; Malhotra and Kaufman 2011). Other proteins expressed 
at these sites include Mitofusin 2 (MFN2) which induces mitochondrial fusion, proteins involved 
in innate immune signalings such as MAVS, STING, and the inflammasome receptor NLRP3, 
AKT protein involved in autophagy/mitophagy, in addition to many various proteins involved in 
Ca2+, lipid, and ER homeostasis (Ilacqua et al. 2017). Dysregulation of these sites of 
ER/mitochondrial contacts in the CNS was shown to be associated with many diseases such as 
ALS. Oxidative stress and disturbance in Ca2+ homeostasis and protein folding in ALS are 
characteristic features of its neurodegeneration (Tadic et al. 2014). 
We showed in our study that NLRX1 modifies the functions of both, the ER and mitochondria. 
NLRX1 also interacts with other proteins at the ER/mitochondrial transitions such as MAVS 
(Allen et al. 2011; Moore et al. 2008) and STING (Dempsey 2016; Deng et al. 2017; Haitao Guo 
et al. 2016). For these reasons, we think that NLRX1 might be situated in the MAM and executes 
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its functions on both organelles. However, the exact localization of NLRX1 and the mechanism 
by which it inhibits Ca2+ release from the ER require more in-depth investigations.  
4.4. Conclusion and future perspectives 
In our work, we provide evidence that NLRX1 enhances astroglial glutamate uptake by 
enhancing mitochondrial functions in astrocytes, that in turn promote the functional activity of 
glutamate transporters. NLRX1 also inhibits astroglial glutamate release by suppressing its Ca2+-
mediated exocytosis. By regulating these two astroglial functions, NLRX1 maintains glutamate 
homeostasis in the CNS and represents a potential therapeutic target for CNS diseases associated 
with glutamate excitotoxicity. 
To our knowledge, this is the first time to be reported that one protein can regulate both 
processes, and therefore, it regulates glutamate homeostasis in the CNS. 
As a continuation of the current work, further investigations on the exact location of NLRX1 
in the mitochondria and the mechanism by which NLRX1 modulates Ca2+ release from the ER is 
essential to understand better how NLRX1 regulates glutamate release by astrocytes. 
As a first step, we obtained our results from in vitro experiments on healthy mouse astrocyte 
cultures. As a second step, it would be necessary to confirm the role of NLRX1 in glutamate 
homeostasis in healthy CNS in different animal models. Future studies should also evaluate the 
role of NLRX1 in glutamate excitotoxicity in various animal models of inflammatory and 
neurodegenerative diseases in the CNS such as brain trauma, CNS infections, ALS, and MS. 
As a recently discovered molecule, most of the obtained data on NLRX1 were based on in 
vitro studies using cell lines or primary animal cell cultures, and in vivo experiments on Nlrx1-/- 
versus WT mice. However, very minimal or limited studies involved the role of NLRX1 in human 
diseases. These studies included the expression of NLRX1 in different human diseases such as 
COPD (Kang et al. 2015), ATN and ACR (Stokman et al. 2017), and the nlrx1 mutation associated 
with CHB virus infection susceptibility (Zhao et al. 2012). There is only one study in the CNS 
evaluated the nlrx1 gene expression in patients with ruptured brain aneurysms (Theus et al. 2017). 
Based on these data, future studies should be directed more towards the role of NLRX1 in human 
diseases inside and outside the CNS. As a continuation of our study, the effect of NLRX1 on 
glutamate uptake and release should be evaluated in human astrocytes. The level of expression of 
NLRX1 should be determined in patients with various CNS diseases. Attention should be payed 
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more towards the study of the protective role that NLRX1 may play against the development and 
progression of these diseases specially those associated with glutamate excitotoxicity such as 
neurodegenerative diseases and MS. 
All the currently used treatments for glutamate excitotoxicity reduce the toxic effects of 
glutamate on the postsynaptic neurons. Among these treatments, riluzole, which blocks glutamate 
neurotransmission in the CNS and blocks NMDA receptors in the postsynaptic neurons (Doble 
1996). Memantine is another anti-glutamatergic drug that acts as a non-competitive NMDA 
receptor antagonist. It is currently used for treatment of moderate to severe Alzheimer’s disease 
(Alam et al. 2017). NLRX1, as a regulator of glutamate homeostasis, enhances glutamate uptake 
and inhibits glutamate release by astrocytes. Therefore, it represents a potential novel therapy that 
not only prevents the toxic effect of glutamate on neurons, but it inhibits the onset or the primary 
causes of excitotoxicity. As a long-term perspective, future studies should focus on the possibility 
to use NLRX1 as a therapeutic target for CNS diseases associated with glutamate excitotoxicity. 
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